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 ABSTRACT 
Lack of patient adherence with medication results in health care costs 
and adverse clinical outcomes. Although fear of side effects can contribute to 
non-adherence, being informed about them can actually improve matters. 
Nonetheless, questions persist as to the most efficient way to convey that type 
of information to patients for a given medication. Information on side effects is 
largely limited to a simple list in medication leaflets, often without frequency 
data (that is, lacking detail as to how often they might occur). The decision-
making literature suggests that the interpretation of information varies 
depending on the presentation format or the frame used. 
This study examined the impact of providing numerical information for 
side effect frequency, levels of illness severity, and side effect framing on the 
likelihood of taking an OTC medicine. 
Participants received a headache scenario with three drug options (X, Y 
and Z) to consider for use. These painkillers had three levels of potency 
(defined as 50, 75, and 100% effective) and were accompanied with three 
levels of side effects (two, four, and six items). When considering their drug 
choice for the headaches, participants received drug information written without 
side effect frequency data, then again with side effect frequency data. Subjects 
rated their likelihood of taking Drug X, Y and Z on a scale of 1 (very unlikely) to 
100 (very likely). Participants were also asked to show their likelihood of taking 
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 a different set of two medications for headaches (coined Drug N and P) based 
on positively-slanted or negatively-slanted wording in relation to chances of 
experiencing a side effect (heartburn). 
Thirty subjects from Saskatoon over 50 years of age participated. The 
average age was 66.6 years and 63.3 percent of participants were female. Less 
than half of participants (n=11) had previous experience with side effects. Most 
participants were using at least one medicine (whether OTC or prescribed) and 
described themselves as knowledgeable or somewhat knowledgeable.  
Participants were more likely to take the hypothetical drugs in the 
situations described when they received frequency data for side effects 
(p<0.05). Also, there was a significant higher mean likelihood of use when the 
drug was framed positively (p<0.01).  
When considering decisions involving drug effectiveness and their side 
effects, the provision of frequency data increased patient likelihood of use. 
Framing the context in positive format also increased patient likelihood to use a 
medicine. This information could be important for pharmacists counselling on 
medication side effects, especially for those patients with medication adherence 
problems. 
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 CHAPTER 1 
INTRODUCTION 
 Over the past 30 years or so, there has been a growing awareness of the 
need to provide people with information about their illnesses and associated 
treatments. The process of successful medicine-taking is likely based on a 
partnership between patients and health care professionals. It is necessary that 
patients and their caregivers have two-way exchange of  information and views 
about medicines.1 In line with this, a number of studies have reported beneficial 
effects of giving people health-related information.2,3 
 Pharmacists often convey drug-related information to patients through 
the use of computer-generated leaflets, but the value of such documents has 
been questioned, due in large part to the extensive lists of side effects within 
them. It has been suggested that such a comprehensive style may in fact scare 
patients into states of non-adherence. Yet, researchers have found patients 
who received such leaflets knew more about their medicines (especially the 
side effects) and were significantly more satisfied.4-8 Others support the value of 
written information for increasing patients’ knowledge and adherence with 
treatment.2,3 
 In addition to written information, pharmacists convey information 
verbally. Evidence suggests pharmacists display a broad range of approaches 
when counselling patients about their medicines – some provide extensive 
information while others are more selective. In a small Canadian study, Dyck et 
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 al. found that pharmacists discussed side effect information with all patients, but 
only half of patients received information on the drug’s benefits.7 Side effects 
that were raised were often described with respect to occurrence using terms 
and phrases such as “might happen”, “rarely”, and “not that common”.  
 One type of information noted to cause particular difficulties in terms of 
patient and health professional understanding is the presentation of risk 
information.9 Patients want and need understandable information about the 
risks of medicines. The best predictors of adherence are patient attitudes, 
beliefs, and perceptions about their illness and treatment.10 These include 
whether patients perceive a medicine as necessary for maintaining health, as 
well as concerns about possible adverse consequences such as unpleasant 
side effects, dependency, or long term harm. This is essential if they are to 
become partners in medicine-taking. 
 The use of verbal descriptors to convey information about side effect risk 
may lead to over-estimation of the level of harm and may lead patients to make 
inappropriate decisions about whether or not they take a medicine.11 It appears 
that patients may prefer numerical (e.g. 4 percent or 4 out of 100) rather than 
verbal descriptors (rare, infrequent, common, etc) and are able to use that 
format to make more accurate predictions of their personal likelihood of 
experiencing a particular reaction.2,7,9,12,13 Also, studies show patients who were 
informed in terms of natural frequencies were less anxious about taking their 
drugs.9,14-17 A study by Timmermans showed that risks presented as population 
figures were perceived as having the greater chance of occurring compared 
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 with percentages and frequency formats.18 However, Hawley et al. evaluated 
the ability of six graph formats to impart knowledge about treatment 
risks/benefits to individuals with low and high numeracy ability. They found 
communicating probabilities with pictographs would be particularly useful 
among lower numeracy individuals.19 Careful attention to information 
presentation allows the less numerate to understand and use numbers more 
effectively, especially in risky decisions. It is important that a physician or 
pharmacist be aware of the meaning patients may attach to a probability 
expression during a consultation.20,21 Where individual differences exist, a 
health care provider should consider presenting probability information in more 
than one format to make sure a message has been delivered properly. 
 While many reports suggest that the public wants more information about 
their drug therapy,5,11,22-35 simply providing more volume may be less desirable 
than striving for more effectiveness. There is a need to synthesize the current 
evidence on patient preferences for different information formats and assess 
the effects of various forms of delivery.2,36 For instance, little is known about 
how many adverse effects should be mentioned for a given drug before the 
informational load becomes unmanageable.  
 The content of counselling will vary depending on whether a prescription 
(Rx) or an over-the-counter (OTC) drug is involved. When considering patient 
counselling workload, pharmacist priority will also be different regarding the 
formulation of drug (e.g. inhalation or injection) and the seriousness of the 
condition. Where a drug is known for a high risk of interactions or adverse 
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 effects, this information would likely be more emphasized by pharmacists. 
Overall, the length of counselling a patient receives will be influenced by other 
factors such as lack of privacy, knowledge about drugs and conditions, 
communication skills, and time.  
 There is even less research on agents available without a prescription 
(over-the-counter or OTC). Standard OTC counselling textbooks encourage 
pharmacists to approach patients and offer them information about OTC drugs, 
to make sure the benefits and risks have been explained.23 Yet, according to a 
2003 US national survey, only 43 percent of people consult a pharmacist when 
buying an OTC drug.23 Patients often do not ask the pharmacist for advice 
because they believe they know all that is necessary or because they are 
unaware of potential problems. 
 OTC medicines are commonly used to treat minor illnesses. Though 
most Canadians believe that such medicines are safe and effective, they can 
have adverse effects and interactions with other agents.35,37,38 People in 
Canada can purchase OTC medicines from pharmacies, or for select agents, in 
non-pharmacy outlets such as convenience stores. Given that people are being 
encouraged to be more active in their care and to select their own medicines, 
they must have clear information to choose and use them effectively. 
 Bissell found consumers emphasize the benefits and effectiveness of 
OTC medicines rather than their risk.38 In this study, the researchers chose an 
OTC hay fever medicine (terfenadine) that has known potential for interactions 
with a number of antibiotics and anti-fungal agents. These interactions were 
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 purported to have caused 33 cases of serious cardiac arrhythmia at the time, of 
which 14 were fatal. As a result, terfenadine was re-classified from OTC to 
prescription-only status. After release of this news, in interviews with 94 
consumers purchasing OTC medicines, they found consumers were far more 
likely to talk about the benefits of such medicines, and rarely referred to the 
risks or dangers of medication unless prompted by the researcher. The majority 
of consumers’ views regarding OTC medicines were that those available in a 
pharmacy must be safe and less dangerous than prescription medicines. 
Another study regarding the use of non-steroidal anti-inflammatory drugs, which 
are available OTC at pharmacies, found that patients were more likely to 
overuse OTC drugs than prescribed drugs.39 There is more to be learned about 
how consumers of OTC medicines process product-related information. 
 In summary, valuable information is accruing on the extent to which 
patients consider the use of prescribed medicines in relation to side effects. Far 
less is known as to how this relates to the use of OTC medicines. When a 
pharmacist counsels a patient on the use of such a medicine, s/he will have to 
consider how best to convey the benefits and risks of use. However, many 
purchase decisions in pharmacies regarding OTCs take place without 
pharmacist involvement. In these situations, it is the written information on the 
box or product insert that must convey the information. Current medication 
packaging and inserts usually provide lists of adverse effects with no indication 
for frequency of occurrence. Such information may be useful in helping a 
patient estimate the degree of risk to which s/he will be exposed, in relation to 
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 any expected relief of symptoms. Because of this lack of knowledge, this study 
will examine aspects of how OTC medicine users process side effect 
information when considering product use. 
 
1.1. Objective 
 During the process of informing patients about a medicine, including the 
potential for side effects to occur, variations in approaches might affect patient 
likelihood of taking that medicine. This study examines provision of numerical 
data for side effects and the effect of this information on patient medicine-
taking behaviour. A secondary focus will investigate the impact of numerical 
information formatted in negatively-slanted or positively-slanted phrasing.  
 The objective of this study was to determine how citizens of Saskatoon 
are influenced when given numerical risk estimates of side effects and differing 
phrasing formats. 
 
1.2. Research Questions 
1) What is the impact of varying levels of side effect potential and drug 
effectiveness, when considered concurrently, on perceived likelihood of 
taking a medicine?  
2) What is the impact of providing percentages and frequency occurrences of 
side effects on the likelihood of taking a medicine? 
3) What is the impact of illness severity on the likelihood of taking a medicine? 
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 4) What is the impact of presenting side effect information within a negatively-
or positively-slanted context on perceived likelihood of taking a medicine? 
 
1.3. Null Hypothesis 
1) There is no difference on perceived likelihood of taking three hypothetical 
drugs when varying levels of side effect potential and drug effectiveness 
are considered concurrently.  
2) There is no difference on perceived likelihood of taking three hypothetical 
drugs when providing the public with natural frequency and percentages of 
side effect occurrences. 
3) There is no difference on perceived likelihood of taking three hypothetical 
drugs across two levels of illness severity. 
4) There is no difference on perceived likelihood of taking a drug when 
presenting side effect information within a negatively- or positively-slanted 
context. 
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 CHAPTER 2 
LITRATURE REVIEW 
Hundreds of thousands of people a year visit physicians for a multitude 
of ailments. For many, a medicine is prescribed, with intent to promote a higher 
state of health. Compliance is the extent to which a patient's behaviour 
coincides with health care provider advice.40 Although the term compliance is 
widespread and is still in use, the World Health Organization (WHO) formulated 
a definition of compliance and renamed it adherence. The WHO definition for 
adherence is: “the extent to which a person’s behaviour (taking medication, 
following diet, and/or executing lifestyle changes) corresponds with agreed 
recommendations from a health care provider”.41 The main difference between 
compliance and adherence is that adherence requires the patient’s agreement 
on the recommendation. The term adherence is intended to be non-judgmental; 
it is an observation of a fact and not intended to blame the patient.  
A patient is more likely to follow a regimen when there is agreement 
between physician and patient, and the patient has confidence in the medical 
diagnosis and prognosis. The process is complicated by uncertainty about the 
nature of an illness and the effects of treatments, particularly medications.40 The 
prevalence of low adherence to medication regimens is of concern for the 
health care system and society because waste is incurred if suboptimal 
therapeutic outcomes are returned for the resources invested to provide drug 
therapy. The following facts reflect the nature of the problem: 
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  It is estimated that approximately 30 to 50% of prescribed medication is not 
taken as directed;42-44 
 One in five patients will not comply with their medications,45 even after 
receiving mail and telephone reminders;45,46 
 In Canada, the cost of non-adherence is approximately $7 to $9 billion 
annually;45 
 125,000 patients die in the United State every year because of non-
adherence;22 
 10 percent of hospital visits are due to non-adherence;22,45 
 28 percent of hospital visits for the elderly are due to non-adherence.45 
Various patient and health professional factors have been considered for 
their effects on adherence, including specific barriers (e.g. cost and access) and 
communication failure.23,44 The latter involves situations where the patient does 
not know, understand, or remember what has been prescribed.23,24,44 Yet, even 
when there are no obvious barriers and when patients are well informed about 
their treatment, they still may not comply with it. This is deemed to be 
intentional non-adherence.43 Here, patient beliefs are usually the key 
determinants. Patients may have negative beliefs about medicines in general; 
they may be seen as unnatural, harmful or over-prescribed by doctors or as 
having negative outcomes such as adverse effects or dependence.44  
Some authorities have presumed that discussing adverse effects with 
patients would increase non-adherence due to fear,11,23-27 but this does not 
appear to be the case in all instances. Fear of adverse effects can contribute to 
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 non-adherence, but being informed about side effects can resolve fears.11,23-27 
In a survey about the risks of drugs, 90 percent of patients reported that 
precaution and warning information would encourage them to take the drug 
exactly as prescribed.47 
Communicating medication information effectively should help patients 
make personal decisions about treatments and find ways to integrate 
medication-taking into their daily activities. To be effective, health professional 
interaction with patients should involve strategies that modify the patient’s 
health beliefs and attitudes.23  
 To understand a message about adverse effect risk, readers need to 
know the population at risk and how this risk compares to other risk. Improving 
public understanding of risk is a problem (but also an opportunity) that involves 
multiple players, including those in traditional print and broadcasting news, 
entertainment, advertising, public health, health communication, clinical 
medicine, scientific research, government at all levels, and professional and lay 
advocacy groups.48 The target is the public; but there is no single “public”. 
There are publics not only in terms of sex, age, and geography, but also in 
terms of individual risk susceptibility, exposure, and risk literacy. Risk literacy, in 
essence, is defined as the acquisition and application of a body of knowledge 
about risk. This includes a familiarity with the nature of risk and risk-taking, an 
ability to specify and use suitable risk assessment approaches, and an ability to 
deal appropriately with risk issues that have been identified.49 It also could be 
defined as a basic grasp of statistics and probability that is critical to making 
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 choices about health, money and even education, yet it is largely ignored by the 
national curriculum. Often, those at greatest potential risk are less likely to be 
informed about the risks they face or able to understand the complex, changing 
data involving health hazards.48 Conversely, many of the most voracious 
consumers of health information are a more capable, literate audience. They 
may be better informed, but also at lower risk, because they are already taking 
good care of their health and have greater access to the health care system. To 
make inroads into the difficult task of improving health risk understanding 
across the board, one must address diversity of health care consumers in the 
real world.48 Past research suggests that among seniors whose health is at high 
risk, literacy levels may be very low.  
Literacy skills can have a direct effect on a person’s health in the use of 
prescription drugs. The potential for medication errors is enormous among 
those unable to understand written directions properly, or among those who are 
unable to decipher the written text. Elderly patients will experience this problem 
to a much greater degree since they are more likely to use medication and take 
several drugs simultaneously. The International Adult Literacy and Skills Survey 
tested more than 23,000 Canadians aged 16 years or more in 2003 on their 
skills proficiency in four domains: prose, document, numeracy and problem-
solving.50 Skills were rated on the basis of levels one to five (lowest to highest). 
About 42 percent of adults between the ages of 16 and 65 scored below level 
three on the prose literacy scale and when those aged 66 and over were also 
included, the proportion scoring below level three in prose literacy increased to 
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 nearly one-half (48 percent). At 55 percent, the proportion of the population 
aged 16 and over with numeracy scores below level three was even more 
pronounced. Levels below three are considered to indicate limited proficiency, 
while levels about three indicate high proficiency. Even in the top performing 
jurisdictions at least three out of ten adults aged 16 and over performed at the 
lowest levels in prose and document literacy and at least four out of ten adults 
performed below level three in numeracy. These individuals are likely to have 
difficulties coping with increasing literacy- and numeracy-related demands 
common in everyday life.50 
 
2.1. Decision-making in Today’s World 
 In general terms, a decision is the selection of an action among 
alternatives. Alternatives must be available and in most markets, contemporary 
consumers are usually offered a wide range of product choices.51  
Decision-making involves evaluating information and making a choice 
among several possible alternatives which have different costs, benefits, and 
consequences. Decisions might involve uncertainty or risk.52 Unfortunately, in 
facing uncertainty, people might not consider each of the relevant branches of a 
decision tree.53 Decision-making situations may also require a degree of 
knowledge or computational skill that is beyond what humans can do. Further, 
when making decisions, a person can stray beyond factual information into 
uncertain territory.52 
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 Expected utility theory states that when faced with uncertainty in choice, 
people make decisions based on two factors – the expected utility (i.e. the 
attractiveness of consequences) and the respective probability of the 
outcomes.52 Utility refers to the outcome a person would like to achieve, such 
as health, wealth or happiness. In other words, utility refers to the perceived 
value derived from a decision. So basically, people weigh the good that might 
come out of each alternative against the costs of that alternative. Decision-
makers also assess the probability of alternative outcomes to inform their 
decisions.  
Choices should not vary with how options are presented. However, 
preference reversals indicate they do.52 Preference reversal means switching 
preferences for one outcome over another based only on how these outcomes 
are presented. The expected utility model does not fully explain how people 
make choices in many circumstances because it assumes too much; humans 
rarely, if ever, have all of the information necessary to make a decision. Even if 
they did, they may lack the ability to combine and comprehensively weigh the 
information logically. Expected utility proposes that people base their decisions 
on expected consequences, but there is no real way to foresee consequences 
with certainty.52 
Prospect theory, as developed by Kahneman and Tversky, is concerned 
with behaviour of decision-makers who face a choice between two 
alternatives.52,54 Decisions between alternative actions are associated with 
probabilities (prospects) or gambles. Prospect theory assumes that people 
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 make decisions based on what they have right now and how they interpret 
gains and losses on different scales, with losses being more psychologically 
powerful than gains.52-55 This theory predicts the framing effect, whereby people 
are risk-averse when faced with certain gains and risk-prone when faced with 
certain losses.52 The researchers found that people underweigh outcomes that 
are merely probable (in comparison with outcomes that are obtained with 
certainty) and also that people generally discard components that are shared by 
all prospects under consideration.54 In addition, some studies noted people lend 
too much weight to small probabilities and too little weight to larger 
probabilities.22,56 
The research on framing indicates that people make different choices 
depending on how the alternatives are framed. According to the psychological 
accounting principle, people make different decisions depending on how each 
outcome is perceived.52 Consider the following scenarios: 
 
1. Imagine that you have decided to see a play where admission is $10 
a ticket. As you enter the theatre, you discover that you have lost a 
$10 bill. Would you still pay $10 for a ticket to the play? 
 
2. Imagine that you have decided to see a play where admission is $10 
a ticket. As you enter the theatre, you discover that you have lost the 
ticket. The seat was not marked, and the ticket cannot be recovered. 
Would you pay $10 for a ticket to the play? 
 
In these scenarios, what is being manipulated is not the cost or benefit, but the 
way that participants are likely to think about the extra $10 that needs to be 
spent. Results showed that participants were less willing to purchase a ticket in 
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 scenario 2. Why should this be? In this scenario, $10 has already been invested 
for the play, so spending another $10 seems an unattractive alternative. In 
scenario 1, people think they simply lost $10, money that could have been 
spent for anything. So it seems that participants were less averse to losing 
money from their general “psychological account” than they were from their 
“play account”, which already had been tapped for the $10 play ticket. In both 
scenarios, we are out $20, and we get to see a play, so there should be no 
difference in our willingness to spend 10 more dollars.52 
Another variation on the notion of psychological accounting relates to 
what has been termed the sunk-cost effect. The sunk-cost effect is the 
tendency to continue investing, even in the face of loss. The sunk-cost effect 
states that people attribute too much weight to the resources already invested 
in a particular course of action as a decision criterion.52 
Another study of the framing effect in decision-making found that a 
preferred option and a less preferred option may differ in magnitudes. Such 
discrepancies are called valence effects. Yamagishi and Miyamoto observed 
systematic positive valence effects (“better” exceeding “worse”) in the domain of 
gains and systematic negative valence effects (“worse” exceeding “better”) in 
the domain of losses.57 Preferences under the framing effect switch from certain 
options in the domain of gains to uncertain options in the domain of losses. 
How do people make decisions in risky choice situations? When people 
have access to information sources such as newspaper weather forecasts, 
drug-package inserts, and mutual-fund brochures, all of which provide 
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 convenient descriptions of risky prospects, they are making decisions from 
description. When people must decide whether to back up their computer's hard 
drive, cross a busy street, or go out on a date, however, they typically do not 
have any summary descriptions of the possible outcomes or their likelihoods. 
For such decisions, people rely on experience. Decisions from experience and 
decisions from description can lead to dramatically different choices.58  
Description-based decisions tend to overweigh the probability of rare 
events, as described by prospect theory. Hertwig et al. found that experience-
based decisions tend to underweigh the probability of rare events.58 They 
proposed two different theories of risky choice: 1) in decisions from experience, 
rare events had less impact than they deserved; 2) in decisions from 
description, rare events had more impact than they deserved.58 But how does 
direct experience lead to underweighing? Decisions from experience depend on 
the sampled information, so any account of how such decisions are made ought 
to consider how people search for information and how the results of the search 
affect subsequent decisions. 
 
2.2. Decision-making Involving Drug Therapy 
Times have changed regarding the nature of decisions involving use of a 
drug. Patients of previous generations merely needed to decide whether to 
seek medical attention; it was generally not their place to question the advice 
given. Physicians tended to fill a paternalistic role, maintaining exclusive 
purview over medical knowledge. The expectation of both providers and 
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 consumers of health care was that the physician knew what was best. Today, 
roles and expectations for information have shifted, giving way to the newer 
model of informed choice and active patient participation in health care.59 
However, while improvements have been made, imbalances in relationship 
power most likely still exist.  
Patients must be adequately informed about treatment alternatives and 
outcomes before they can participate in the decision-making process. Given 
that the manner of presentation of such outcomes can influence such decisions, 
greater use of written and electronic tools might serve to clarify choices for 
patients. However, decision aids alone are not likely to replace the human 
element in facilitating informed choice. In theory, it might be better to couple 
descriptive or quantitative information with high-quality decision counselling 
(e.g. use of pictographs) to help patients understand the potential risks, 
benefits, and uncertainties of clinical options that best accommodate their 
personal preferences.59 When treatment effects are described to patients, a 
balanced presentation of the information should enable patients to make 
informed decisions.60 
 
2.3. Challenges to Informed Patient Decision-making 
In general, there are three main goals of treating a patient: 1) to make 
the patient feel better; 2) to reduce the risk of future disease complications; and 
3) to improve survival. There are those who include a fourth goal – economic 
benefit – both to the patient and to society, but Furberg notes that economic 
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 benefit represents a natural consequence of reaching one or more of the three 
main goals.61 
Providing the data needed to make informed medical decisions is a 
challenging task.28,62 People deciding whether to use a medication need reliable 
evidence on the benefits and harms. Unfortunately, reliable evidence of harm is 
often lacking, in part because reporting of harmful effects is incomplete.63 
Emotional and psychological barriers are also involved in the reporting of harm. 
There are many issues that may need to be clarified before a health care 
provider can confidently counsel a patient, but the main three are: 1) the goals 
of treatment; 2) the intended benefit of a treatment; and 3) the potential harms 
of a treatment. Regarding that potential harm, clinicians should address the 
issue at an appropriate depth and breadth of patient understanding to support 
informed choice about potential side effects of drug treatment, thereby covering: 
1) the nature of an adverse effect of the medication; 2) the seriousness of the 
adverse effect; 3) the likelihood and uncertainty of experiencing the adverse 
effect; and 4) whether there are therapeutic options to reduce the potential for 
adverse effects. 
A common complaint of patients is that a prescribed medication makes 
him/her feel worse. The problem can range from something simple such as 
dryness of the mouth to serious adverse events that may require the treatment 
to be stopped. Even simple adverse effects can be very distressing to the 
patient, thereby reducing adherence. Adverse effects with a gradual onset are 
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 the most difficult to detect because the patient may not attribute them 
immediately to the treatment.  
Occasionally, drugs may have serious adverse effects such as allergic 
reactions, hepatitis, cardiac arrhythmias or gastric ulcer. Despite this, attributing 
an adverse event to a specific treatment can sometimes be difficult, particularly 
when the event is rare, unexpected, or appears a long time after the start of 
treatment. It can also be difficult to recognize an adverse effect when it occurs 
as part of the natural history of the underlying condition. 
Direct-to-consumer advertising of drug products often neglects to 
mention all known side effects and provide incomplete risk information to 
consumers. Davis provided an example which emphasizes the issue: 64 
Imagine two drugs that work identically and that have the same set of 
side effects. One drug is advertised with an incomplete risk statement 
and the second is advertised with a complete risk statement. Harm 
(through loss of sales) is done to the second drug’s advertiser if 
consumers prefer the first drug over the second because of the 
difference in the number and types of side effects reported in each drug’s 
risk statement. Psychological and physical harm also can be done to 
consumers should they request the first advertised drug over the second, 
thinking that they can avoid some of the side effects associated with the 
second drug, but then experience some of side effects not noted in the 
first drug’s incomplete risk statement. 
 
The researcher explored the relationship between the completeness of the risk 
statement describing drug-associated side effects (the risk statement) and 
consumers’ perceptions of a drug’s safety and appeal.64 The study design 
manipulated risk statement completeness with regard to the incidence of side 
effects mentioned and the presence or absence of a numeric indicator of side 
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 effect incidence. Results strongly suggested a direct relationship between risk 
statement completeness and consumer perceptions of drug safety and appeal. 
Consumers rated the safety and appeal of drugs described with an incomplete 
risk statement significantly more positively than comparable drugs described 
with a more complete risk statement. 
The Food and Drug Administration (FDA) called for comments regarding 
advertising of prescription drug products directly to consumers. Smith stated 
that, more than ever, consumers want the facts, and in no place is that more 
apparent than in direct-to-consumer advertising. Meeting the FDA's fair balance 
mandate provides an accurate and fair assessment of the risks as well as the 
benefits, but what is missing is the concept of trust.65 Another response by the 
staff of the Bureau of Consumer Protection also noted:66 
The FDA should make clear that the fair balance requirement for direct-
to-consumer ads prohibits only ads that convey a deceptive impression 
of the risk and benefits from the overall presentation of information, 
rather than those that fail to achieve a mechanistic balance between 
risks and benefit information because they do not present such 
information with identical emphasis.  
 
Pharmaceutical companies now must move beyond simply meeting fair balance 
requirements and seek the trust of consumers reading their ads. Only then will 
consumers be willing to take the next step: deciding that the benefits of taking a 
medication outweigh the risks.  
People and organisations may have competing interests, or come under 
pressure to take a lenient approach, for reporting harm. Little gratitude is to be 
expected by a health care provider or an institution reporting that the 
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 interventions they offered were harmful.61,63 The federal government has 
suggested that physicians should be required to report drug-related side effects 
that occur in their patients. At the moment, reporting is voluntary for physicians, 
as it is for pharmacists. 
Informational needs, decision-making styles, and ability to use data vary 
widely among patients. Everyone who has to explain risk should also 
understand the instinctive bias that the public typically brings to their judgments. 
Effective communication has to take into account the realities of how people 
reason.67 Studies show that framing medical information has an effect on 
patients’ decision-making on whether or not to follow treatment.68,69 There is 
always the possibility of misunderstanding, even when patients and doctors use 
identical words. Paling states that “it is pretty obvious that, if the patient doesn’t 
have the health care provider’s knowledge and context, all such descriptive 
words are likely to mean widely different things to different patients.”67 As an 
example, a group of researchers investigated how readers interpreted the level 
of likelihood intended by “a low risk”. They found that some individuals 
interpreted it as meaning odds as high as one in five, while others said they 
would expect the term to be used for odds of one in 10,000; it depended on 
people’s knowledge or expectations of the context.67  
When a decision involves a drug, a physician and/or pharmacist is (for 
the most part) charged with the task of communicating information to the user. 
Effective communication is associated with improved patient satisfaction, better 
adherence, improved health outcomes, more informed medical decisions, 
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 reduced malpractice suits, and likely contributes to reduced costs of care.70 
Many patients want and need comprehensive and accurate information about 
their medicines and some want full disclosure of associated risks so they can 
participate in decisions about their care.14,71 Effectively communicating even the 
simplest and most unthreatening of messages to a diverse audience is in itself 
difficult, but the reality is that the problem of communicating complex medical 
information and risks to patients can’t be avoided.71 
 
2.4. The Art and Science of Patient Counselling 
 Pharmacists have a professional and ethical responsibility to assist and 
instruct patients on the appropriate use of medications. The processes of 
informing patients about medicines are defined as patient counselling. When a 
new prescription is presented in a pharmacy, a few rudimentary questions are 
initially asked, and then the prescription is filled. The pharmacist will call for the 
patient to return to the dispensary counter and the process of counselling 
begins. The name, indication, route of administration of the medication, storage 
instructions, and refill information will be stated. Patients should also be told 
about the side effects that may occur and what they can do to prevent or 
minimize them. Generally, a pharmacist will mention certain items verbally and 
support the process with a more comprehensive printed version of information 
(the so-called medication information leaflet or handout). Time of counselling 
will vary depending on whether the customer is a new patient or a returning 
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 patient. When a medicine is a refill of a chronic medicine, less information is 
presented on the assumption that the person was previously counselled. 
 The counselling protocols suggested by Rantucci note that patient needs 
vary and pharmacists need to recognize these situations and understand the 
issues involved.23 Certain points in the counselling may need to be emphasized, 
and the various materials, methods, and techniques used in counselling may 
need to be altered. Pharmacists have reported that many factors contribute to 
challenges in patient counselling. These factors include characteristics of the 
patient, the type of drug prescribed or condition being treated, and various 
aspects of the situation. In addition, there are factors involving the individual 
pharmacist that contribute to challenges.  
 Patient counselling is an integral part of the pharmaceutical care 
model.72 Pharmaceutical care is defined as the responsible provision of drug 
therapy for the purpose of achieving definite outcomes that improve a patient’s 
quality of life.73 In order to provide pharmaceutical care, pharmacists must 
accept responsibility for their patients' drug-related problems and re-design their 
practices in a manner that facilitates this level of care.74 
 Implementation of a pharmaceutical care plan, the decisions about drug 
use, and monitoring of therapeutic outcomes require consultation with the 
patient.23 In the community pharmacy setting, the patient is the pharmacist's 
main source of information.72 The patient can contribute to the identification of 
problems and should play a role in the formulation of treatment goals and 
regimens. Researchers have established that communication between 
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 pharmacists and patients is important for improving appropriate medication use 
and achieving desired outcomes.75 Pharmacist counselling can improve patient 
adherence, therapeutic outcomes, and quality of life. Also, it can decrease 
adverse drug reactions, the number and cost of medications, emergency room 
visits, hospitalizations, length of stay in hospitals, and overall health care 
costs.76 
Counselling should consist of a two-way discussion between patient and 
pharmacist. But, pharmacists often view counselling as a one-way process in 
which they tell or lecture the patient about their medication. A two-way 
discussion may be more time-consuming, but has the potential to positively 
affect patient understanding and compliance.72 Two-way communication uses 
open-ended questioning and other methods to ensure the patient has input into 
the process; it means there is a balance of pharmacist and patient talk.  
The pharmacist must often decide the extent of detail that is appropriate 
on the basis of several considerations. One consideration is that of the patient’s 
rights to know about their drug treatments, alternative treatments, and possible 
risks of treatment. Another consideration is the pharmacist’s perception of the 
patient’s ability to understand the information based on the patient’s educational 
background. The pharmacist should weigh these considerations for each 
individual patient and situation, but the needs of the patient identified during 
information gathering and care plan development phases of counselling should 
be the ultimate guide to the selection of information.23  
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 A study by Wolf et al. examined the common causes for the 
misunderstanding of prescription drug warning labels among adults with low 
literacy.77 Patients were asked to interpret and comment on eight commonly 
used warning labels found on prescription medications. Patients with low 
literacy skills demonstrated a lower rate of correct interpretation than did those 
with higher literacy skills. Multiple-step instructions, reading difficulty of text, the 
use of icons, the use of color, and message clarity were the common causes of 
label misinterpretation.77 
 Effective patient counselling is not simply the provision of information. 
Information is prerequisite to compliance, but the timing and organization of the 
message and involvement of the patient are also critical in determining what the 
patient understands and remembers. Pharmacists are experts on drug therapy, 
but patients contribute information about their daily routines, how they 
understand their illness and their treatments, and whether they anticipate any 
problems taking the medicine as prescribed. Each of these points needs to be 
assessed if counselling is to be effective.78 
 Lack of communication between the patient and their care providers is a 
problem in medicine and pharmacy. Efforts have been made to improve 
communication, especially in community pharmacies.28 Traditionally, patient 
information provided by community pharmacists has focused on technical 
aspects of the use of medicines and applicable reimbursement rules.72 Now, 
pharmacists are trying to move away from a drug-focused, paternalistic 
approach in patient information, to providing customized information according 
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 to patient needs.23,72 It requires knowledge and skills beyond product 
knowledge about medicines.  
 Greater involvement of patients in decisions about their treatment is 
predicated on the patient having access to understandable information.11 The 
quality of the pharmacist-patient relationship and the content and style of the 
communication may also be crucial to improving patient counseling.23,79  
During the provision of prescription drug information, individuals often do 
not control how much (or what) information the health care practitioner 
provides.80 By extension, evidence of information overload exists in the health 
care literature. Labor et al. reported perhaps the obvious, that individuals who 
received too much written information about a medication were more likely to be 
confused and overwhelmed than those who received an amount that was right 
for them.4 Similarly, a study by Schommer et al. investigated individuals’ 
processing of prescription drug information under different conditions of 
presentation.80 Study materials were mailed to 624 volunteers living in the 
United States, of which 477 (76.4 percent) returned completed data forms. The 
results suggest there is a balance between the need for information at a level 
sufficient for individuals to make decisions and the need for information that will 
not overload individuals as they cognitively process it. Results indicate that 
study subjects who received written information reported lower levels of 
cognitive effort (less confusion). Understanding and remembering the 
information presented in the consultation may have been easier with written 
medication information, which they could refer to later. Study subject perception 
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 of cognitive effort increased as both the breadth and depth of the information 
increased. A balance may be needed – greater depth likely requires less 
breadth, while more breadth of information may need less depth (information 
with simple wording). 
 Hahn et al. reported an inverted U-shaped relationship between 
information load and decision quality. Individuals with too little or too much 
information made poorer decisions compared to those with an amount of 
information that was of sufficient breadth and depth.81 Individuals can select the 
most important information from the total, but useless or less relevant 
information can dilute the effects of more important information on judgments.80  
 
2.5. Side Effects as a Component of the Counselling Process 
In medicine, uncertainties are abundant.15 The benefit of using an agent 
and the side effects of treatment may be uncertain. In practice, clinicians 
frequently communicate information about uncertainty to the patients by verbal 
probability estimates,15,82 using descriptive words such as rarely or uncommon. 
A study of how family physicians value the use of numerical formats for talking 
with patients, and how confident they were with each mode of communication, 
showed that 189 of 300 agreed that communicating risk both qualitatively and 
numerically was equally important.82 Of the remaining 111 physicians, 94 
percent endorsed the importance of communicating qualitatively more strongly 
than numerically. In terms of relative confidence, 104 of 300 (34.7 percent) felt 
equally confident in their qualitative and numerical communication skills. Of the 
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 remaining 196, 97 percent were more confident in communicating qualitatively 
than numerically. However, Edwards et al. reported higher anxiety among 
patients receiving verbal description about risks than numerical descriptions.69 
Within this process, a health care professional may choose to use numerical 
probabilities expressed as either percentages or frequencies.  
Communicating the risk of medication side effects to patients is often 
suboptimal. The side effect sections of patient information leaflets generally 
provide a list of all possible side effects with no indication of individual 
risk.11,17,83 Studies have shown medication guides in their current form are 
unlikely to be useful to patients,2,11,17,25-27,83,84 especially those with limited 
literacy skills.84 Adverse effects listed without frequency or percentage data may 
make it harder to understand individual risk.11,26 Research suggests that such 
information is the highest priority for patients 17,28,83,85-87 and that the perception 
of them is influential in many patients’ decisions about taking a medicine.27 
 
2.5.1. Patient / Provider Perceptions of Demand for Side Effect Information 
 The public appears to want more information about drugs. A review by 
Raynor et al., with a focus on patient interest in reading prescription information 
leaflets (PILs), noted that 40 to 89 percent of consumers read written 
medication information (depending on the type of written information they 
received).2 Airaksinen and colleagues surveyed the public and pharmacists in 
Finland on the aspects of drug information each felt was important to receive.28 
The opinions of these two groups differed remarkably on several items. For the 
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 public, the highest perceived need was for information about adverse effects 
and interaction with other drugs, with 79 percent definitely wanting this 
information. In contrast, pharmacists thought the most important things that 
customers should be told about were dose instructions (78 percent) and storage 
information (74 percent). Information on side effects was given a lower priority 
by pharmacists, with only 13 percent saying it must be given.  
 In a study by Barnett et al., an intervention to foster patient participation 
in medication counselling was tested in community pharmacies.72 This 
intervention consisted of a written prompt, instructing patients who were waiting 
for new prescriptions to write prescription-related questions they wished to ask 
their pharmacist. The pharmacist then used the questions as an aid in 
counselling. The findings showed that 56 of 106 patients told to write a question 
for the pharmacist did so. All but two of these patients wrote three questions or 
less. The most common questions related to side effects (52 patients); whether 
the medicine should be taken with food (14); interactions with food or medicines 
(12); how to take the medicine (11); and how the medicine works (10). 
 Berry et al. presented participants with a brief hypothetical scenario 
about a visit to the doctor (which entailed being prescribed some medication) 
and were then asked to list the questions they would like to ask.87 There was 
considerable consistency in responses, with the most frequently asked 
questions being about side effects, what the medication actually does, what 
lifestyle changes might be involved, and how to take the medication. 
Conversely, studies have shown that doctors hardly discuss adverse effects 
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 with patients.1 Smith and Henderson forwarded an interesting view of how 
physicians discuss adverse effects of antipsychotic medications.88 They noted 
that doctors inform patients about the adverse effects of medication, but are 
highly selective with regard to which side effects they feel ready to discuss with 
patients. This might not correlate with what patients may wish to be told. This 
study concluded that discussing side effects with patients needs to be more 
comprehensive than current practice.  
 Physicians continually face the problem of how much detail concerning 
risk for adverse effects they should provide patients. Although patients have a 
moral right to full disclosure, patient surveys are contradictory regarding how 
much side effect information they want. Most people appear to want to know all 
potential adverse reactions, even if they are relatively rare.3,29-32,71 However, it 
has been suggested by health care workers that to explain to patients (for each 
medication prescribed) every possible adverse effect would clearly be a task of 
unacceptable time and questionable advisability.3 How then is the physician to 
choose what level and extent of information to give? A study by Ziegler et al. 
found that most individuals desire all information concerning possible adverse 
effects of prescribed medication and do not favour physician discretion in these 
decisions.3 Among 2500 adults who filled out a 12-item questionnaire, the 
feedback was: 76.2 percent wanted to be told of all possible adverse effects; 
13.3 percent only if an adverse effect occurred one in 100,000 times; 10.2 
percent only if such occurrence was one in 100 times; while 0.4 percent were 
not interested in any information. Elsewhere, Åström et al. found that providing 
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 information about medicines to patients who desire it makes them more 
satisfied and empowered, whilst providing information to those who do not want 
it makes them more anxious and less empowered.33 
 
2.5.2. Presenting Side Effect Information to the Public 
 The question of whether to inform patients about possible side effects of 
prescribed medication has given rise to considerable debate in recent years. On 
one hand, several studies have shown that patients do want to be told about 
possible side effects. On the other hand, many doctors believe that informing 
patients about side effects might reduce adherence with the medication.16 
Studies that have directly addressed this question have generally found that 
informing patients about side effects does not increase the incidence of their 
occurrence, nor does it have a negative effect on adherence.16,34 Some studies 
reported provision of detailed information about possible adverse 
consequences of treatment can improve patient understanding and satisfaction 
without unnecessary anxiety.5,32  
Howland et al. investigated whether patient education leads to drug side 
effects, a situation called suggestion-induced side effects.89 Ninety-eight adults 
treated with erythromycin (for a variety of illnesses) were randomized into two 
groups: one group received patient education about side effects, while the other 
group was given no such information. Overall, 10 percent of the uninformed and 
eight percent of the informed group felt that the erythromycin bothered them in 
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 some way. There were no significant differences in the occurrence of various 
individual side effects. 
 Most current mandatory medicine information lists side effects without 
frequency data.11 In 1999, the European Union (EU) produced a guideline on 
the readability of leaflets, which indicated that the frequency of side effects 
could be denoted by the use of five verbal descriptors (very common, common, 
uncommon, rare, very rare) as an alternative to numerical incident rates (see 
Table 2.1). The intent was to help standardize language already in common 
use. 
 
Table 2.1 European Union verbal descriptors of side effect  
  probability and allocated frequencies 
Descriptor Probability 
Very common >10 % 
Common 1-10 % 
Uncommon 0.1-1 % 
Rare 0.01-0.1 % 
Very rare <0.01 % 
 
 
 Several studies have examined how people interpret the set of verbal 
probability labels as proposed for use by the EU guideline. They found that both 
members of the general public and patients visiting a cardiac clinic consistently 
over-estimated the risk of side effects when presented with the recommended 
descriptors, and that this in turn affected their perception of risk to health and 
their likelihood of taking the medicine in question.11,14,17,26,35 Based on EU 
verbal descriptors, very common is set at more than 10 percent risk, but this 
was interpreted to mean 54 percent risk by readers. Very rare was set at less 
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 than 0.01 percent and was understood by readers to equate to four percent risk 
(see Table 2.2). 
 
Table 2.2 Comparison of EU verbal descriptors of side effect probability  
  and allocated frequencies with level of risk understood by 
readers11,17,26,83 
EU terminology Level of risk Level of risk understood by reader 
Very common        >10% 54-65% 
Common       1-10% 34-45% 
Uncommon      0.1-1% 11-18% 
Rare 0.01-0.1%       8% 
Very rare     <0.01%       4% 
 
 Some studies that evaluated the influence of verbal descriptors on 
people’s medicine-taking behaviours suggested use of numerical data when 
describing risk, in order to avoid confusion of estimated risk.11,14,17,26,35,83 
Regarding this content, a study done in England looked at the 50 most 
prescribed medicines and found that 40 percent of medication leaflets had no 
information on the likelihood of adverse effects, 12 percent used EU terms, 40 
percent used a wide range of other verbal descriptors and eight percent 
provided numerical indication of risk.86 
 It has been established that people tend to attribute too much weight to 
lower probabilities and too little weight to higher probabilities.56 This leads to 
misconceptions about the likelihood of uncommon events, which influences 
their behaviour in a wide array of domains. If people unreasonably over-
estimate their risk for side effects, this may subsequently reduce adherence.22,83 
Because pharmaceutical companies and pharmacists frequently present risk 
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 information semantically, patients might perceive their risk to be much greater 
than clinical trial results would suggest.  
 The way risk information is communicated plays an important role in how 
people understand risk, accept or deny risk, and deal with risk information. 
Typically, side effect information is disclosed using ambiguous semantic 
descriptions, such as “some people may experience …”, “side effects may 
include …”, and “commonly reported side effects are …”.11,12,22,36 These 
semantic descriptors do not express the exact percentage of risk and are 
subject to personal interpretation. Disclosing the actual percentages associated 
with side effects may improve the accuracy of people’s risk estimates. However, 
there has been little evidence-based guidance on how best to communicate that 
information.12,36 
 Young and Oppenheimer proposed that informing a person of actual 
percentage risk of side effects might reduce fear and increase intentions for 
adherence.22 The aim of their studies were to investigate whether commonly 
used methods of conveying side effect risk might influence peoples’ perception 
of their risk, then whether disclosing this information as actual percentages 
might subsequently influence their intentions to comply with the medication.22 
Results showed respondents expressed a stronger intention to comply with 
their prescribed treatment regimen when they received percentage information 
compared to those who received the semantic framing. Those in the group 
receiving percentages also expressed less fear of experiencing drug-related 
side effects than those in the semantic group. 
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  In a review, Edwards et al. found that terms such as probable, unlikely, 
and rare convey elastic concepts.36 In other words, one person’s understanding 
of likely may be a chance of one in 10, whereas another may think that it means 
a chance of one in two. Individuals may interpret those terms differently in 
different contexts -- for example, a rare outcome is a different prospect in the 
context of genetic or antenatal tests than in the context of antibiotic treatment 
for tonsillitis.  
 Interpretation of numerical information can also be problematic. 
Yamagishi found that a death rate of 1286 out of 10000 was rated as more risky 
than a rate of 24.14 out of 100.56 This study showed that perceived riskiness 
would increase when risks were presented as relative frequencies using larger 
numbers. 
 The psychological literature on decision-making also suggests that the 
interpretation of information varies depending on the presentation format or the 
frame used. For example, if a person is told of a 30 percent chance of survival 
(positive frame), it is obviously equivalent to a 70 percent chance of mortality 
(negative frame).60 Positive framing (chance of survival) is more effective than 
negative framing (chance of death) in persuading people to take risky 
options.36,68 A comprehensive review has also indicated that among patients, 
messages framed in terms of losses may be more effective in promoting the 
uptake of screening than those framed in terms of gains.69  
Schwartz et al. conducted a medical data interpretation test and found 25 
percent of participants who received information framed around death (nine in 
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 1000 people die from this surgery), rated “nine in 1000 chance of death” as 
riskier than “991 in 1000 chance of surviving”. On the other hand, 61 percent 
rated both as having the same risk, while 14 percent rated the chance of the 
surviving frame (991 in 1000 people survive this surgery) as riskier than the 
chance of death.20 
Another study by Gurm and Litaker found that patients were more likely 
to opt for angioplasty treatment when told that it was 99 percent safe, compared 
with a one percent likelihood of a serious complication.68 Positive framing, 
therefore, affects people’s treatment preferences and it has been shown to 
improve their understanding of the information presented. 
There is indirect evidence that probability concepts are intrinsically 
difficult for humans.20,21,90-94 Hoffrage et al. offer persuasive evidence that when 
prevalence, sensitivity, and false positive rates were given as probabilities (e.g. 
10 percent), even physicians misinterpreted the information in a way that could 
be potentially disastrous for the patient. But when they were presented as 
natural frequencies (e.g. 10 cases in 100), physician performance was 
dramatically better.92 Accordingly, studies suggest that one way to improve both 
communication of statistical information and medical education is to use natural 
frequencies rather than probabilities.21,90-96 Presenting information in a 
frequency format also has broader implications, for its application can be 
employed in a wide spectrum of medical decision-making. 
 Berry et al. found that people’s perception of risk and their stated 
likelihood of taking a particular medicine are substantially affected by the 
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 adverse effect information they are given.26 In one report, results showed that 
when negative information was given about possible side effects, people gave 
lower ratings, both in terms of how good they believed the explanation to be, 
and their perceived likelihood of taking the medication.32  
 Knapp et al. found that verbal descriptors were associated with more 
negative perceptions of the medicine than their equivalent numerical 
descriptors.11 Bergenstrom and Sherr found verbal expressions of probability to 
be vague and subject to individual interpretation.15 Therefore, in applied 
practice, it is important to codify the meaning of verbal probability expressions, 
especially as it relates to risk and health decision-making.15  
 
2.5.3. The Importance of Inclusion of Benefit Information to the 
Counselling Process  
 A study by Bersellini and Berry examined the effectiveness of simple 
benefit statements on people’s judgments about a medicine.95 They found that 
when participants received information about benefits of medications (without 
side effects), it did not influence their intention to comply. The reason was that 
people assumed prescribed medicines had side effects, even when there was 
no reference to these in the scenario. In another experiment, they examined 
two kinds of benefit information, but included side effects for the medicine. 
Patients were told the medicine was associated with four side effects and found 
that both forms improved patient intention to comply.95 The study provided 
support for the inclusion of benefit information in medicine information leaflets, 
particularly to balance concerns about adverse effects.  
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  Dyck et al. studied pharmacist communication skills when counselling on 
medication side effects.7 They videotaped the patient counselling approaches of 
10 pharmacists to examine how they equipped patients with knowledge about 
medication management and side effects. The results indicated that the 
pharmacists used vague terms such as sometimes, might, and may to describe 
side effects, as opposed to citing the frequency of possible occurrence from 
clinical studies. The pharmacists also spent less time discussing the overall 
benefits of the medications and focused more on medication safety issues. 
Further, the authors noted that a majority of the pharmacist-patient encounters 
did not facilitate effective two-way communication. The researchers concluded 
that patient satisfaction and treatment compliance may be challenged as a 
result of inadequate pharmacist-patient communication. The inclusion of benefit 
information to information leaflets has been suggested by some other studies 
too, as a way to balance concerns about adverse drug reactions.12,69,96,97 
 
2.6. Summary 
 How to convey risk information to patients is a developing science. More 
information is needed on how best to inform potential medicine users about side 
effects. This is especially true for OTC medicines. Research was therefore 
undertaken to address how providing risk of medication side effects in 
numerical format would affect patient medicine-taking behaviour. The format for 
presenting the numerical data was also examined (positively- versus negatively- 
slanted wording).  
 
 
38
 CHAPTER 3 
METHOD 
 This study was designed to obtain data on public perceptions of various 
methods for conveying risk information about OTC medicines and the 
subsequent influence these perceptions have on the tendency to use medicine. 
It had three components:  
  1) Demographic and attitudinal information 
  2) Presentation of scenarios 
  3) Participant interviews 
 
3.1. Participants 
Participants were residents of Saskatoon who were 50 years of age or 
older. Older citizens were chosen because they are more likely to take 
medicines than their younger counterparts. Participants had to have English as 
their first language and have reached a pre-determined score on the Rapid 
Estimate of Adult Literacy in Medicine98 (REALM) test (discussed below). 
Subjects were recruited using posters (see Appendix A) placed in 30 
randomly chosen pharmacies and recruitment brochures placed in prescription 
bags (subsequent to interest shown by a patient). Pharmacists were allowed to 
use professional discretion in determining which patients might be appropriate 
for this study. The researchers of this study had no contact whatsoever with a 
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 pharmacy’s clientele to this point. The letter requesting pharmacist help for 
recruiting is available in appendix B. 
 Patients who were interested in participating were asked to call the 
researchers to gain entry into the study. If requested, additional information was 
sent to potential participants or clarifications were made over the phone. 
Recruitment was complete when 30 patients meeting the entrance 
requirements had volunteered. Power considerations did not drive the sample 
size calculations for this study, since effect size and standard deviation values 
were not available at the time. Rather, past research involving patient interviews 
of a like-minded report guided the decision to enlist 30 subjects.38 Issues such 
as time and budget limitations were also factors. 
 Before initiation of the study, participants were provided with information 
on study procedures and what was expected of them. Participants were divided 
into two groups. Odd-numbered participants (based on their order of contact 
with the researcher) were assigned to a mild headache scenario, while even-
numbered participants were assigned to a severe headache scenario 
(discussed below). 
Appointment times were made over the phone to accommodate the 
preferences and schedule of participants. It may have been difficult for older 
adults not familiar with the University of Saskatchewan campus to find parking, 
then find their way to the Thorvaldson building where the study was to be held. 
To counter this, participants were provided with an option of being paid for their 
parking meter or their bus pass to partake in the study. The researcher also 
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 walked them from University Hospital parking to the building where the study 
took place and then walked them back to their cars. In some cases, the 
researcher met people at an off-campus site that was more convenient for 
them.   
Participants who had REALM scores of less than 19 would have been 
excluded from the study because they would not be able to read the medicine-
based information of the study materials. However, no participants scored less 
than 19.  
 
3.2. Procedures 
 Those agreeing to participate were asked to come to the study site for a 
period of approximately one hour. An honorarium of $30 was provided for their 
time plus $3 for parking or bus pass. 
 Appointment times were scheduled over the course of two months. At 
the time of arrival and before the study commenced, participants were provided 
with a form (Appendix C), inviting them to provide written consent to participate 
in data collection and interviewing for the study. Written permission was also 
obtained from participants for the tape-recording of interviews (Appendix D). 
After consent forms had been obtained, a brief orientation to the project was 
undertaken. Then, subjects were given the study materials to complete. A 
researcher was present to answer questions, but caution was used in order to 
prevent over-guidance during this step. 
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 In the first phase, participants answered questions on age, gender, 
education level, experience with medication side effects, and some questions 
regarding expectations of pharmacists and medication leaflets (see Appendix 
E). Questions regarding side effects and expectations from pharmacists were 
created by the researchers, except for question 14 in Form 1 which has been 
taken from another study (Ziegler et al.3). It should be noted that for this study, 
we replaced physicians with pharmacists in the statement (Physicians should 
give as much information concerning side effects as he or she thinks best for 
the individual patient). 
Next, to ascertain existing attitudes towards medicines, the Beliefs about 
Medicines Questionnaire43 (BMQ) was administered (see Appendix F). The 
BMQ is a questionnaire for assessing patients’ perceptions of medicines from a 
health psychology perspective. Two major themes can emerge for beliefs about 
medicines in general: general-harm and general-overuse. The first comprises 
beliefs about the intrinsic nature of medicines and the degree to which they are 
perceived as fundamentally harmful. The second comprises beliefs about the 
way in which medicines are used, particularly the extent to which they are 
perceived to be over-prescribed by doctors. Participants were asked to indicate 
to what extent they agree or disagree (5=strongly agree, 4=agree, 3=uncertain, 
2=disagree, and 1=strongly disagree) with statements about medicines in 
general: 
 Doctors use too many medicines (General-Overuse) 
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  People who take medicines should stop their treatment for a while every 
now and again (General-Harm) 
 Most medicines are addictive (General-Harm) 
 Natural remedies are safer than medicines (General-Overuse) 
 Medicines do more harm than good (General-Harm) 
 All medicines are poisons (General-Harm) 
 Doctors place too much trust on medicines (General-Overuse) 
 If doctors had more time with patients they would prescribe fewer medicines 
(General-Overuse) 
Scores could range from four to 20. Higher scores (20) on the BMQ-
general would mean a strong belief that medicines are either overused by 
doctors (i.e. BMQ-overuse) or harmful and addictive (BMQ-harm).  
To gauge existing health status, a short form health survey (SF-8) was 
used99 (see Appendix G). Scores could range from eight to 42, where eight 
would mean no physical or mental health concerns and 42 would mean physical 
and emotional problems exist.  
The REALM test was used to determine the health literacy of subjects98 
(see Appendix H). 
Finally, a measure of numeracy was given using two sets of questions 
(condensed version) from Schwartz et al.20 and Woloshin.62 Of a total of six 
questions, four questions were numerical probability problems, while two 
questions examined reasoning ability regarding risk probability communication 
(see Appendix I). The four questions pertaining to probability and frequency 
were posed as follows:   
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 1) Imagine that we flip a coin 1000 times. What is your best guess about 
how many times the coin would come up heads in 1000 flips? [500 
times out of 1000 is the correct answer] 
 
2) In the Big Bucks Lottery, the chance of winning a $10 prize is 1%. 
What is your best guess about how many people would win a $10 
prize if 1000 people each buy a single ticket to Big Bucks? [10 
persons out of 1000 is the correct answer] 
 
3) In the ACME Publishing Sweepstakes, the chance of winning a car is 
1 in 1000. What percent of tickets to ACME Publishing Sweepstakes 
win a car? [0.1 percent is the correct answer] 
 
4) Mrs. Smith is told she has a 1 in 296 chance of dying from cancer 
and a 1 in 407 chance of dying from a stroke. Which is bigger, Mrs. 
Smith’s chance of dying from a stroke or cancer? [cancer is the 
correct answer] 
 
Participant responses to these questions were assessed based on the number 
of correct answers.  
 Participant responses to positive and negative numerical presentation of 
a risk associated with surgery were explored in two kinds of framing: 9 in 1000 
people die from this surgery versus 991 in 1000 will survive. Participants were 
asked to show how risky they felt this surgery was by choosing one of four 
options presented (very risky, risky, slightly risky, and not risky). The responses 
were assessed to see if participants chose the same level of riskiness for both 
surgeries (the correct interpretation). The time required to complete phase one 
was approximately 15-20 minutes.  
In the second phase, TWO studies were carried out back-to-back. In 
Study 1 (see Appendix J), a design was chosen to allow comparisons of patient 
choices based on: 
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 A. Variation in drug efficacy and side effect potential for hypothetical 
situations where a participant could choose one of three fictitious 
drugs (arbitrarily called Drugs X, Y, and Z) for symptomatic relief of a 
headache 
 
B. Variation in the severity (mild or severe) of the symptom in question 
(headache) 
 
C. Variation in the extent that information was presented (± probability 
data) with respect to side effect frequency rates 
 
 In Study 2 (see Appendix K), a design was chosen to allow comparisons 
of patient preference based on the use of positively- or negatively-slanted 
phrasing in the presentation of side effect frequency. This was done using two 
fictitious drugs (Drug N and P), with each associated with one side effect 
(heartburn). The difference between Drug P and N, therefore, was the format of 
numerical presentation in describing the frequencies with which heartburn 
would present. Drug P was presented in a positively-slanted format, while Drug 
N was in a negatively-slanted format. The time required to complete phase two 
was approximately 15-20 minutes.  
During the third phase, individual interviews were carried out to garner 
more in-depth understanding of the decisions made during Studies 1 and 2 of 
phase two. Appendix L shows the steps for how the interviews were conducted. 
The time required to complete each interview of phase three was approximately 
15-20 minutes.  
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 3.3. Category of Medicines for Consideration 
 Of the vast array of medicines that could be considered, only those 
available OTC were chosen. One that is used for a common ailment (headache) 
was considered so that participants would have reasonable potential for 
familiarity with the symptom under consideration. Support for this was a global 
health survey conducted by The Nielsen Company which found headaches to 
be one of the most common minor ailments.100 Nearly half of those polled had 
claimed to have suffered a headache in the last four weeks. When it comes to 
the treatment of this common ailment, consumers often purchase OTC 
products. 
An actual brand name or recognizable generic name was not used. 
Rather, the terms Drug X, Drug Y, and Drug Z were the options presented to 
participants. It was thought this might prevent direct association to agents they 
may have used in real life. Precedence for this approach exists in other 
research. A number of studies used fictitious names such as Epidoxin or 
Flavocin (antibiotic) for participants responding to a scenario involving a sore 
throat or ear infection.25,27,95,101-103 Schwartz et al. assessed patient medical 
data interpretation skills using an imaginary drug called Gritagrel.20 Young and 
Oppenheimer used Drug X as a hypothetical drug name for their study.22 
 
3.4. Side Effects Chosen for this Study 
 For the execution of Study 1, common side effects (and the 
corresponding frequencies) were chosen from product monographs of Advil®, 
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 Motrin®, Tylenol®, and Aspirin® (Lexi-Comp online and e-CPS circa 2007). By 
design, severe and very rare effects were not utilized. Table 3.1 shows some 
OTC and Rx medications for relief of headache and their possible side 
effects.104 The side effects utilized in this study for Drug X, Y, and Z were 
therefore similar and relevant to real medication for relief of headache. Further 
justification for the selected side effects was provided by Young and 
Oppenheimer.22 They found, based on 20 randomly chosen advertisements, 
that the most commonly occurring side effects were diarrhoea (reported in 18 of 
20 advertisements), headache (17 of 20), and nausea (17 of 20). For 11 
selected advertisements, the most frequently occurring side effects were 
dizziness (10 of 11), diarrhoea (11 of 11), and nausea (11 of 11). 
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 Table 3.1 Headache medicines and their possible side effects104 
Generic Name  Brand 
Name  
Use  Possible Side Effects  
Acetaminophen 
 (OTC) 
Tylenol Pain relief Few side effects if taken as 
directed, although they may include: 
changes in blood counts and liver 
damage 
Aspirin (OTC) Bayer, 
Bufferin, 
Ecotrin 
Pain relief Heartburn, Gastrointestinal 
bleeding, Bronchospasm or 
constriction that causes narrowing 
of the airways, Anaphylaxis (life-
threatening allergic reaction), Ulcers
Fenoprofen (Rx) Nalfon Prevention of tension 
headaches; migraines; 
hormone headaches 
Nausea, Diarrhoea, Indigestion, 
Dizziness, Drowsiness 
Flurbiprofen (Rx) Ansaid Prevention of tension 
headaches; migraines 
Treatment of tension 
headache; migraines 
Gastrointestinal upset, Drowsiness, 
Dizziness, Vision problems, Ulcers 
Ibuprofen (OTC) Advil, Motrin 
IB, Nuprin 
Treatment of tension 
headache; migraines 
Gastrointestinal upset, 
Gastrointestinal bleeding, Nausea, 
Vomiting, Rash, Liver damage 
Ketoprofen (Rx) Actron, 
Orudis KT 
Prevention of tension 
headaches; migraines 
Treatment of migraines 
Gastrointestinal upset, 
Gastrointestinal bleeding, Nausea, 
Vomiting, Rash, Liver damage 
Nabumetone (Rx) Relafen Prevention of tension 
headaches; migraines 
Constipation, Heartburn, Diarrhoea, 
Nausea, Vomiting 
Naproxen (Rx) Aleve Prevention of tension 
headaches; hormone 
headaches  
Treatment of migraines 
Gastrointestinal upset, 
Gastrointestinal bleeding, Nausea, 
Vomiting, Rash, Liver damage 
Diclofenac (Rx) Cataflam Treatment of tension 
headache; migraines 
Stomach upset, Bloating, Dizziness, 
Drowsiness, Loss of appetite 
Ketorolac (Rx) Toradol Treatment of tension 
headache 
Gastrointestinal upset, Drowsiness, 
Dizziness Vision problems, Ulcers 
Meclofenate (Rx) Meclomen Treatment of tension 
headache 
Nausea, Diarrhoea, Indigestion, 
Dizziness, Drowsiness 
Carisoprodol 
(Rx) 
Soma Treatment of tension 
headache 
Dizziness, Drowsiness, Nausea, 
Headache, Nervousness, Skin rash, 
Bleeding 
Orphenadrine 
citrate (Rx) 
Norflex Treatment of tension 
headache 
Drowsiness, Dizziness, Headache, 
Nervousness, Blurred vision 
Cyclobenzaprine 
HCL (Rx)  
Flexeril Treatment of tension 
headache 
Dry mouth, Drowsiness, Dizziness 
Metaxalone (Rx) Skelaxin Treatment of tension 
headache 
Drowsiness, Dizziness, Headache, 
Nervousness 
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 3.5. Design 
3.5.1. Study 1: Provision of Frequency Data for Side Effects 
 The sample of 30 participants in the study was divided into two arms. 
HALF of participants were given the FIRST hypothetical scenario, where the 
headache was described as mild but common: 
 
Whether true or not, consider for a moment that you get headaches. 
They tend to be mild and occur 6 times a year. You need a pain killer 
for these headaches in order to focus better on your daily activities. You 
have the choice of the following 3 headache medicines for relief.  
 
The other HALF were given the SECOND hypothetical scenario, where the 
headache was severe but rare:  
 
Whether true or not, please consider for a moment that you get 
headaches. They tend to be severe and occur twice a year. You need a 
pain killer in order to get out of bed. You have a choice of the following 3 
headache medicines for relief. 
 
The only methodological difference between these two groupings of participants 
was the scenarios.  
 All participants, regardless of their scenarios, then received two 
variations in side effect presentation for the three drugs (Drug X, Y, and Z):  
 
1) Side effects without frequency data included  
2) Side effects with frequency data included  
 
Participants were first asked to consider three medicines (Drug X, Y, Z) with no 
frequency data (without) included for the side effects. The three agents under 
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 consideration were characterized from lower efficacy (with few potential side 
effects) up to high efficacy (but more potential side effects). While all three were 
“effective”, one was 50 percent effective and had two side effects, the second 
one was 75 percent effective and had four side effects, while the third was 100 
percent effective and had six side effects. A graphical illustration of this is as 
follows:  
 
 
Drug X                                      Nausea 
50% effective                            Rash 
 
 
Drug Y                                      Nausea 
75% effective                            Rash 
                                                  Dizziness 
                                                  Heartburn 
 
Drug Z                                      Nausea 
100% effective                          Rash  
                                                  Dizziness  
                                                  Heartburn  
                                                  Diarrhoea  
                                                  Dry eyes  
 
 Subjects were then asked consecutively: “How likely is it that you would 
take Drug X?”, “How likely is it that you would take Drug Y?”, and “How likely is 
it that you would take Drug Z?” Their answers were recorded on a Visual 
Analogue Scale of 100 points (from very unlikely to very likely) [see Form 6 in 
Appendix J]. Subjects were also asked to outright choose one of these drugs as 
the preferred agent.  
 Next, these same participants received the same list of side effects with 
frequency data, but added at this juncture were the percentages (and 
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 frequencies) for how often side effects might occur. Subjects were still given the 
choice of using Drug X, Y, and Z for their headache. As before, subjects again 
were asked: “How likely is it that you would take Drug X?”, “How likely is it that 
you would take Drug Y?”, and “How likely is it that you would take Drug Z?” 
Their answers were again recorded on a Visual Analogue Scale of 100 points 
(from very unlikely to very likely) [see Form 7 in Appendix J]. As before, 
subjects were again asked to choose outright one of these drugs as the 
preferred agent after seeing the percentages and frequencies of side effects. 
An illustration of the inclusion of frequency data for this process is as follows: 
 
Drug X                                      Nausea 3% (3 in 100) 
50% effective                            Rash 4% (4 in 100) 
 
 
Drug Y                                      Nausea 3% (3 in 100) 
75% effective                            Rash 4% (4 in 100) 
                                                  Dizziness 7% (7 in100) 
                                                  Heartburn 5% (5 in 100) 
 
 
Drug Z                                      Nausea 3% (3 in 100) 
100% effective                          Rash 4% (4 in 100) 
                                                  Dizziness 7% (7 in100) 
                                                  Heartburn 5% (5 in 100) 
                                                  Diarrhoea 2% (2 in 100) 
                                                  Dry eyes <1% (less than 1 in 100) 
 
This design would allow a comparison in mean likelihood of taking drugs 
without percentages versus with percentages for side effects, given that 
responders would be exposed to both styles.  
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  Participants were asked to choose one of the agents for their headache. 
Options were Drug X, Drug Y, Drug Z or none. In essence, the choice would 
involve balancing between level of efficacy desired in relation to its associated 
side effects. By design, all participants responded to the preference question 
twice, once without frequency data and again with side effect frequency data 
[see question 4 in Form 6 and question 8 in Form 7 of Appendix J]. This was 
undertaken to determine if their decision to use a medicine would be affected by 
frequency of side effect occurrence. The outcome could be either a participant 
staying with his/her first choice or changing his/her decision.  
 All participants were asked which style of presentation for side effects 
they would prefer – side effects with no frequency data OR side effects with 
frequency data.  
 
3.5.2. Study 2: Negatively- or Positively-Slanted Presentation of Side 
Effects 
 The goal of this component was to determine if negatively- or positively-
slanted information has any effect on medicine-taking behaviour and which 
approach people prefer (see Appendix J). For this section, subjects were given 
a brief explanation of OTC medicines for headache, ones which have the 
potential to cause a mild side effect (heartburn) when used (see Appendix K). 
Many of the remedies that are used to treat headaches can cause heartburn 
symptoms.105 
 Hypothetical names of drugs were again used so that participants would 
not bring their own experiences with any previously used drugs to this study. 
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 For this, Drug P stood for positively-slanted wording and Drug N stood for 
negatively-slanted wording. Two ways of expressing the same frequency of the 
side effect were presented in both forms: 
 
1) 10 out of 100 people WILL experience heartburn when taking Drug N 
2) 90 out of 100 people will NOT experience heartburn when taking Drug P  
 
Subjects were asked how likely it would be that they would take Drug N and 
Drug P, recorded on a Visual Analogue Scale of 100 points (very unlikely to 
very likely). Then they responded to preferences for the approaches and either 
drug. The sequence of the phrasing was changed for half of the sample, that is, 
group 1 received the negatively-slanted presentation first, followed by the 
positively-slanted phrase, whereas group 2 received the terms in the opposite 
order. This change was to control for presentation order as an influence on the 
decision-making process.  
 
3.6. Interviews 
 Individual interviews were carried out to get more in-depth understanding 
of the decisions made during Studies 1 and 2. See Appendix L for a guide of 
the interview format.  
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 3.7. Ethics 
Approval from the University of Saskatchewan Advisory Committee on 
Ethics in Behavioural Research was obtained on August 28, 2007. In order to 
protect responder confidentiality, surveys and demographics were identified 
only by a participant number and only aggregate data were reported. 
 
3.8. Data Analysis 
Data was analyzed using Chi-Square (gender, numeracy test result, 
levels of education, previous experience with side effects, choice of drugs) for 
comparing the equality of distributions between groups. The Independent t-test 
compared means for the two groups on age, SF-8 health scores, and BMQ 
harm and overuse. Doubly Multivariate Repeated Measures Designs assessed 
the effect of providing percentages for side effects (without percentages vs with 
percentages), the effect of illness severity (mild vs severe headache), and the 
interaction of these two factors. Multivariate design means participants are 
measured on two or more correlated dependent variables (DVs) (or within a 
regression context, two or more predictors). Doubly Multivariate (Repeated 
Measures) Analysis of Variance Design is a design with multiple variables 
measured at multiple times. Doubly Multivariate means that the usual DVs 
serve as one set of multiple variables, while repeated measures serve as a 
second set of multiple variables. In the current study, 30 participants were 
randomly assigned to either the mild headache scenario or the severe 
headache scenario, and were measured on three measures of likelihood of 
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 taking drugs (Drug X, Y and Z) at two points (without percentages and with 
percentages for the various side effects).  
A Paired sample t-test was used to compare the mean likelihood of 
taking Drug P and N. Two-way Repeated Measures Analysis of Variance 
(ANOVA) (factorial design) determined the effect of previous experience with 
side effects and gender on the mean likelihood of taking Drug P and Drug N. 
SPSS (version 15) was used to analyse the data with significance set at 
0.05.  
 
 
55
 CHAPTER 4 
RESULTS 
As a preliminary step toward participant recruitment in September 2007, 
letters were sent to 30 randomly selected pharmacies in Saskatoon. Names 
and addresses for these pharmacies were obtained from the Directory of 
Pharmacies, Saskatchewan College of Pharmacists (June 2007). Based on 
their assistance, recruitment of the 30 study participants occurred over a period 
of two months (September 26th to November 26th).  
As participants entered the study, odd numbers were assigned to group 
1 and even numbers to group 2. Results regarding participants’ ages, gender, 
education level, current medication use, knowledge of medication, experience 
with side effects in the past six months, expectations of pharmacists (with 
regard to side effect information), beliefs about medication (BMQ), health status 
(SF-8), health literacy (REALM) and numeracy are reported in separate 
sections for the 30 participants, as a whole and within their group.  
There was no missing data for individual participants. 
 
4.1. Demographics 
4.1.1. Age 
The age range of respondents varied from 51 to 89 years, with an 
average of 66.6 ± 10.6 years. Independent t-test showed no significant 
difference between the groups’ mean ages (t (28) = -0.254; p>0.05) (Table 4.1).  
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Table 4.1 Age differences for two groups 
Participants N Mean ± SD Std. Error Mean 
Group 1 15 66.1 ± 11.1 2.86 
Group 2 15 67.1 ± 10.5 2.71 
 
4.1.2. Gender 
Of the 30 participants, the majority were female (N=19; 63.3%). The first 
group had six males and nine females and in the second group, five and 10 
respectively. Pearson Chi-Square showed no significant difference among the 
two groups regarding the distribution of gender (χ2 (1) = 0.144; p>0.05).  
Mean age and standard deviation of females and males were 65.6 ± 10.1 
(N=19) and 68.2 ± 11.7 (N=11) years, respectively.  
 
4.1.3. Education Level  
Participants were asked about the education level they had completed. 
Of the 30 participants, five (16.7 percent) had less than grade twelve, four (13.3 
percent) had a high school diploma or equivalent, six (20.0 percent) had some 
university or technical school degree, seven (23.3 percent) had a bachelor’s 
degree, and eight (26.7 percent) held higher degrees (Master’s degree or PhD). 
Table 4.2 shows the distribution of participants between the two groups. 
Pearson Chi-Square test identified a significant difference among the groups 
regarding their level of education (χ2(4) = 9.952; p<0.05), with group 2 being 
more educated. 
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 Table 4.2 Participant level of education 
Groups 
Education level for two groups Group 1 Group 2 Total 
Less than grade 12 5 0 5 
High school diploma 1 3 4 
Some university or technical school education 2 4 6 
Technical school diploma or Bachelors degree 5 2 7 
Masters degree or PhD 2 6 8 
Total 15 15 30 
 
4.2. Baseline Inquiry Questions 
4.2.1. Current Medication Use 
Regarding the current use of Rx and OTC medication, 19 participants 
were taking both types, four were on Rx only, another four were just using 
OTCs, and three were not taking any medication. Overall, 23 participants (76.7 
percent) were taking OTCs and 23 (76.7 percent) were taking Rx medications. 
 
4.2.2. Knowledge of Medication 
On describing their knowledge of Rx and OTC medication (with options 
being very knowledgeable, knowledgeable, somewhat knowledgeable, not very 
knowledgeable, or does not apply to me – I rarely use medicine), 76.6 and 70.0 
percent considered themselves knowledgeable or somewhat knowledgeable for 
OTC and Rx medicines, respectively. On the other hand, 16.6 percent of 
participants described themselves as not very knowledgeable of OTC and Rx 
medicine (Table 4.3). 
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 Table 4.3 Participant knowledge of medication  
Over The Counter Prescribed 
Knowledge of 
medication Group 
1 
Group 
2 
Total Group 
1 
Group 
2 
Total 
Very 
knowledgeable 1 0 1 1 2 3 
Knowledgeable 3 7 10 2 5 7 
Somewhat 
knowledgeable 8 5 13 9 5 14 
Not very 
knowledgeable 3 2 5 3 2 5 
N/A- I rarely use 
medication 0 1 1 0 1 1 
Total 15 15 30 15 15 30 
 
4.2.3. Previous Experience with Side Effects 
In response to the question – Have you had any experience with side 
effects of medication in the last 6 months?, 11 (36.6 percent) reported yes, 
while 19 (63.3 percent) had not had any experience with any. Seven of 11 
participants who had previous experience with side effects mentioned that they 
experienced some of the side effects listed in Study 1 (nausea, rash, dizziness, 
heartburn, diarrhoea and dry eyes), while the other four had experienced 
different side effects (e.g. shortness of breath, muscle pain, among others). 
Pearson Chi-Square showed no significant difference between the two groups 
regarding the distribution of people who had previous experience with side 
effects (χ2(1) = 3.589; p>0.05). Table 4.4 shows the distribution of participants 
with previous experience of side effects among the two groups. 
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 Table 4.4 Participant previous experience with side effects 
Participants Previous experience 
with side effects Group 1 Group 2 
Total 
Yes 8 3 11 
No 7 12 19 
Total 15 15 30 
 
4.2.4. Side Effect Information and Patient Expectations of Pharmacists 
 Participants were asked to indicate to what extent they agreed or 
disagreed with seven statements regarding side effects and how pharmacists 
should be involved in the process (Table 4.5). Choices were strongly agree, 
agree, uncertain, disagree, and strongly disagree.  
 Overall, 84.8 percent either agreed or strongly agreed with all 
statements, 13.8 percent disagreed, while 1.4 percent were uncertain. 
 Almost all participants (96.6 percent) strongly agreed or agreed that they 
would like to receive information about side effects, read medication leaflets or 
written information, and desired detailed information regarding mild and 
frequent side effects. However, 86.6 percent also strongly agreed or agreed 
that side effect information puts them in a position to think twice about taking 
that drug. Table 4.5 shows participants’ responses to each statement. Only 
statement number seven – Pharmacists should put more emphasis on the 
benefits of medications rather than the side effects – varied from this typical 
pattern. Half of participants agreed, while the other half disagreed with this 
statement. 
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 Table 4.5 Information about medication side effects 
Statements SA A U D SD 
I like to receive information about my medication’s 
side effects. 
23 6 0 0 1 
I read medication leaflets or written information 
provided by pharmacists. 
21 8 0 1 0 
Side effect information provided to me puts me in a 
position to think twice about taking that drug. 
13 13 0 4 0 
Pharmacists should give detailed information to all 
individuals regarding mild and frequent side effects. 
19 10 0 1 0 
Pharmacists should give detailed information to all 
individuals regarding mild and rare side effects. 
17 11 0 2 0 
Pharmacists should give as much information 
concerning side effects as he or she thinks best for 
the individual patient. 
16 7 1 6 0 
Pharmacists should put more emphasis on the 
benefits of medications rather than the side effects. 
2 12 2 13 1 
Legend: SA = strongly agree; A = agree; U = uncertain, D = disagree; SD = strongly disagree. 
 
4.3. Health Survey (SF-8) 
The study used the Short-Form Health Survey (SF-8) for assessing 
overall health of participants.99 Scores could range from eight to 42, where eight 
means no physical or mental health concerns and 42 means physical and 
emotional problems exist. The overall mean score for all 30 participants was 
32.4 ± 5.7 and ranged from 22 to 42. This result shows there were some 
concerns about participants’ health. The first group had an average of 32.3 ± 
5.4, with the second group scoring 32.5 ± 6.2. They did not differ significantly 
according to Independent t-test (t (28) = -0.094; p>0.05).  
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 4.4. Beliefs about Medicines Questionnaire (BMQ) 
 Participants were asked to indicate to what extent they agreed or 
disagreed with statements about medicines in general (see appendix F). Higher 
scores (20) for the BMQ-general means a strong belief that medicines are 
either overused by doctors (BMQ-overuse) or harmful and addictive (BMQ-
harm). Scores could range from four to 20. Participants’ responses were 
between four and 18 on this measure. Overall mean and standard deviation for 
BMQ-overuse was 12.8 ± 2.8 and for BMQ-harm was 8.4 ± 2.9 (see Table 4.6). 
Participants were somewhat uncertain about physician overuse of medication, 
but disagreed with the harmfulness of medication. 
 
Table 4.6 Belief of medication in general (BMQ-general) 
BMQ General Participants N Mean* ± SD 
Group 1 15 13.7 ± 2.9 
Group 2 15 11.9 ± 2.6 Belief of medication overuse 
Total 30 12.8 ± 2.8 
Group 1 15 9.5 ± 2.8 
Group 2 15 7.4 ± 2.6 Belief of medication harm 
Total 30 8.4 ± 2.9 
* Scores could range from 4 to 20 
 
Independent t-test compared the two groups for mean scores. There was no 
significant difference regarding the BMQ-overuse (t (28) = 1.792; p>0.05), but 
there was a significant difference for BMQ-harm (t (28) = 2.090; p<0.05), where 
group 1 had stronger beliefs about the harmfulness of medications. 
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 4.5. Rapid Estimate of Adult Literacy in Medicine (REALM) 
The range possible for the REALM test is from 0 to 66 (Appendix H). A 
score above 61 equates to a high school education. Mean score for participants 
in this study was 64.6 ± 3.02, ranging from 50 to 66. This indicates that our 
participants had the ability to read most patient education materials. 
Independent t-test showed no significant difference between the two groups for 
mean scores (t (28) = - 1.412; p>0.05) (see Table 4.7). 
 
Table 4.7 Participant REALM scores 
Participants N Mean* ± SD Std. Error Mean 
Group 1 15 63.8 ± 4.02 1.038 
Group 2 15 65.3 ± 1.23  .319 
* Scores could range from 0 to 66 
 
4.6. Numeracy Test 
 The public’s ability to understand drug information involves digesting 
numerical data. For this reason, an examination of the ability of participants to 
use numerical data (in probabilities and percentages) when interpreting risk 
information in different formats was needed. 
 
4.6.1. Estimate of Numerical Ability to Understand Probabilities 
Four questions related to probability and frequency were posed (see 
appendix I):  
1) Imagine that we flip a coin 1000 times. What is your best guess about 
how many times the coin would come up heads in 1000 flips? [500 times 
out of 1000 is the correct answer] 
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 2) In the Big Bucks Lottery, the chance of winning a $10 prize is 1%. What 
is your best guess about how many people would win a $10 prize if 
1000 people each buy a single ticket to Big Bucks? [10 persons out of 
1000 is the correct answer] 
 
3) In the ACME Publishing Sweepstakes, the chance of winning a car is 1 
in 1000. What percent of tickets to ACME Publishing Sweepstakes win a 
car? [0.1 percent is the correct answer] 
 
4) Mrs. Smith is told she has a 1 in 296 chance of dying from cancer and a 
1 in 407 chance of dying from a stroke. Which is bigger, Mrs. Smith’s 
chance of dying from a stroke or cancer? [cancer is the correct answer] 
 
Participant responses to these questions were tallied according to the 
number of correct answers. The data indicates 26.7 percent (N=8) of 
participants answered all four questions correctly, 13.3 percent (N=4) had three 
correct responses, while 36.7 percent (N=11) answered two correctly (see 
Table 4.8). This means 40 percent of participants have the ability to interpret 
information involving numerical data. However, 23.3 percent would need “more 
explanation” to comprehend numerical data. Pearson Chi-Square showed no 
significant differences between the two groups regarding the distribution of 
correct responds to the questions (χ2(4) = 8.591; p>0.05). 
 
Table 4.8 Participant ability on the numeracy test  
Participants Number of correct 
answers Group 1 Group 2 Total Percent 
None 3 0 3 10.0 
One 0 4 4 13.3 
Two 6 5 11 36.7 
Three 1 3 4 13.3 
Four 5 3 8 26.7 
Total 15 15 30 100 
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 4.6.2. Risk Information and Interpretation of Numerical Data  
 Participants were asked to show how risky they felt surgery scenarios 
were by choosing one of four options presented (very risky, risky, slightly risky, 
not risky). Results demonstrated that 40 percent (N=12) rated 9 in 1000 will die 
as riskier than 991 in 1000 will survive, while 16.7 percent (N=5) rated 991 in 
1000 will survive to be riskier. Only 43.3 percent (N=13) rated the same level of 
risk for both presentations, the correct interpretation. Table 4.9 shows the 
number of people who responded to each statement in each of the two groups. 
Pearson Chi-Square showed no significant difference between the two groups 
(χ2(2) = 4.056; p>0.05). 
 
Table 4.9 Level of riskiness reported by participants 
Participants 
Level of riskiness 
Group 1 Group 2 
Total 
Equal 4 9 13 
9 in 1000 will die is riskier 7 5 12 
991 in 1000 will survive is riskier 4 1 5 
Total 15 15 30 
 
4.7. Study 1: Effect of Numerical Data on Participant Medicine-Taking 
Behaviour 
 Study 1 examined three research questions: 1) the effect of providing 
numerical side effect data on the likelihood of taking medications; 2) effect of 
illness severity on choice of drug; and 3) effect of providing numerical side 
effect data on their choice of drugs when considering drugs effectiveness and 
number of side effects concurrently. 
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 4.7.1. Effect of Providing Side Effect Percentages and Frequency Data 
Participants were given a hypothetical scenario for a headache and then 
were asked to express their likelihood of taking three hypothetical drugs to treat 
it. As before, the visual analog scale used was from 1 (very unlikely) to 100 
(very likely) for likelihood of using it. Half of participants were assigned to the 
mild headache scenario and the other half were assigned to the severe 
headache scenario. 
Three hypothetical drugs – Drug X (50 percent effective with two side 
effects), Drug Y (75 percent effective with four side effects), and Drug Z (100 
percent effective with six side effects) – were options for both groups to treat 
each headache type. The three drugs (Drug X, Y, Z) and the two groups (mild 
and severe headache scenarios) were the independent variables (IVs) in this 
study.  
Participants received two sets of presentations pertaining to the side 
effects. The first presentation only provided a written list of side effects (referred 
to as “before seeing percentages” or “without percentages”), whereas the 
second presentation had a list of side effects with their probability of occurrence 
included (deemed “after seeing percentages” or “with percentages”). The 
likelihood of taking drugs without and with provision of percentages is the DV. 
Table 4.10 shows the mean likelihood to take each type of drug with side 
effects percentages and without side effect percentages per headache 
scenarios (mild and severe). 
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 Table 4.10 Mean likelihood of taking Drug X, Y, and Z with and without side 
effect percentages per headache scenario 
Headache Scenario 
Mild (N=15) Severe (N=15)  Drug Presentation of Side Effects 
Mean* ± SD Mean* ± SD 
Total 
N=30 
Without percentages 50.2 ± 28.9 39.8 ± 26.4 45.0 ± 27.7 
Drug X 
With percentages 62.6 ± 29.3 39.0 ± 21.3 50.8 ± 27.9 
Without percentages 38.1 ± 30.7 50.1 ± 27.8 44.1 ± 29.4 
Drug Y 
With percentages 33.1 ± 28.5 47.1 ± 29.9 40.1 ± 29.6 
Without percentages 37.1 ± 38.1 41.3 ± 32.0 39.2 ± 34.6 
Drug Z 
With percentages 35.2 ± 40.4 64.7 ± 30.9 50.0 ± 38.4 
* Likelihood of taking drugs on a 1-100 scale 
 
The results of the multivariate test of main effects (see Table 4.11) showed no 
significant difference between mild and severe headache groups (F (3, 26) = 
1.814; p>0.05) according to the mean likelihood of taking Drug X, Y, or Z. 
Figure 4.1 shows the mean likelihood of taking Drug X, Y and Z in the mild and 
severe headache groups.  
 
Table 4.11 Doubly multivariate analysis of repeated measure (main effects) 
Effect F df Error df Sig 
Between-Subjects Mild vs Severe  1.814 3 26 .169  
Within-Subjects Without vs With Percentages 3.340 3 26 .035* 
Within-Between Without vs With by Mild vs Severe .802 3 26 .504  
*Sig p<0.05 
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Figure 4.1  Mean likelihood of taking Drug X, Y, and Z with and without 
percentages for side effects per headache scenario 
 
There was a significant within-subject difference when comparing mean 
likelihood of taking the three drugs without side effect percentages to the mean 
likelihood of taking the three drugs with side effect percentages (F (3, 26) = 
3.340; p<0.05). Figure 4.2 shows the mean likelihood of taking Drug X, Y and Z 
with and without side effect percentages, regardless of group factor (mild vs 
severe).  
There was no significant interaction of the mean likelihood of taking all 
three drugs without versus with providing percentages by the two groups (mild 
vs severe headache) (F (3, 26) = 0.802; p>0.05) (see Table 4.11). 
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Figure 4.2  Mean likelihood of taking Drug X, Y, and Z with and without 
percentages for side effects 
 
The univariate test (see Table 4.12) compares the mean likelihood of 
taking (with and without side effect percentages) Drug X (F (1, 28) = 1.219; 
p>0.05), Drug Y (F (1, 28) = 0.696; p>0.05), and Drug Z (F (1, 28) = 1.767; 
p>0.05) separately. The mean likelihood of taking Drug X and Z increased upon 
seeing the percentages, from 45.0 to 50.8 and 39.2 to 50.0, respectively. 
However, there were no significant differences when comparing the mean 
likelihood of each drug separately while considering the with and without side 
effect percentages factor (regardless of group). There was also no significant 
interaction of groups (mild vs severe) when providing the percentages factor for 
Drug X (F (1, 28) = 1.578; p>0.05), Drug Y (F (1, 28) = 0.046; p>0.05), and 
Drug Z (F (1, 28) = 2.458; p>0.05) separately (see Table 4.12). 
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 Table 4.12 Univariate tests for simple effect of providing percentages for 
 each drug and interaction by mild versus severe group 
Source Measure df Error df F Sig. 
Drug X 1 28 1.219 .279 
Drug Y 1 28 .696 .411 Without vs With side effect frequencies 
Drug Z 1 28 1.767 .195 
Drug X 1 28 1.578 .219 
Drug Y 1 28 .046 .832 
Without vs With by 
headache severity (Mild vs 
Severe) Drug Z 1 28 2.458 .128 
 
4.7.2. Effect of Illness Severity on Likelihood of Taking Each Drug  
Further investigation of between-subject effects (mild vs severe 
headache scenarios) demonstrated that the only significant difference was to 
the mean likelihood of taking Drug X (overall mean likelihood of with vs without 
percentages) when comparing the two groups (see Table 4.13).  
 
Table 4.13 Effect of headache scenarios on mean likelihood of taking  
Drug X, Y and Z 
Measure Severity of headache N Mean* ± SD Std. Error 
Mild headache scenario 15 56.4 ± 29.2 5.8 
Drug X 
Severe headache scenario 15 39.4 ± 23.6 5.8 
Mild headache scenario 15 35.6 ± 29.2 6.7 
Drug Y 
Severe headache scenario 15 48.6 ± 28.4 6.7 
Mild headache scenario 15 36.2 ± 38.6 7.2 
Drug Z 
Severe headache scenario 15 53.0 ± 33.1 7.2 
* Likelihood of taking drugs on a 1-100 scale 
 
Participants in the mild headache group reported a higher mean likelihood of 
taking Drug X (56.4 on the scale of 1-100) compared to the mean likelihood of 
taking Drug X (39.4) in the severe headache group (F (1, 28) = 4.312; p<0.05). 
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 Table 4.14 presents test statistic information for effect of groups (mild vs 
severe) by drugs. There were no significant differences between the mean 
likelihood of taking Drug Y in the mild headache group and the mean likelihood 
of taking Drug Y in the severe headache group (F (1, 28) = 1.876; p>0.05). 
There were also no significant differences between mean likelihood of taking 
Drug Z in the mild headache group and the mean likelihood of taking Drug Z in 
the severe headache group (F (1, 28) = 2.752; p>0.05). 
 
Table 4.14 Tests of between-subjects effects of mild versus severe headache 
variables on Drug X, Y, and Z 
Source Measure df Error df F Sig. 
Drug X 1 28 4.312 .047* 
Drug Y 1 28 1.876 .182  Mild vs Severe headache scenario 
Drug Z 1 28 2.752 .108  
*Sig p<0.05 
 
4.7.3. Impact of Varying Levels of Side Effects and Effectiveness of Drug 
X, Y, and Z on Participant Decision to Use a Drug 
To determine the effect of providing percentages for side effects on 
participant decisions to use a medicine (options were Drug X, Y, Z or no drug at 
all), two answers were compared regarding which drug the participants would 
choose if they were experiencing a headache. This was done first without the 
frequency data for side effects and then with the frequency data for side effects. 
Of the 30 subjects, 17 (56.6 percent) kept the same drug, nine (30.0 percent) 
changed to a more effective drug, and four (13.3 percent) participants changed 
to a less effective drug (which also carries less side effects) (see Table 4.15). 
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 Table 4.15  Effect of providing percentages for side effects on participant 
decision to take a drug 
Change in drug choices  Percent N 
Switched to less effective drug with less side effects 13.3 4 
Switched to more effective drug with more side effects 30.0 9 
Did not change their choices of drugs 56.7 17 
Total 100 30 
 
4.7.4. Impact of Illness Severity on Drug Choice 
Participant choices of drugs also differed in relation to the mild versus 
severe headache scenarios. Pearson Chi-Square showed a significant 
difference between drug categories and illness severity for both methods of 
presenting side effects, that is, without and with percentages (χ2 (3) = 11.083; 
p<0.05 and χ2 (3) = 10.597; p<0.05), respectively. Table 4.16 shows the 
frequency of participants in the two groups who preferred Drug X, Y, or Z 
without provision of percentages for side effects and with provision of 
percentages.  
 
Table 4.16 Chosen drug for mild and severe headache scenario groups 
Severity of headache scenarios  Preferred drug Mild headache Severe headache  Total 
None 1 3 4 
Drug X 9 1 10 
Drug Y 1 6 7 
Drug Z 4 5 9 
Without 
percentages 
Total 15 15 30 
None 1 0 1 
Drug X 9 2 11 
Drug Y 0 4 4 
Drug Z 5 9 14 
With 
percentages 
Total 15 15 30 
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 4.7.5. Preferred Presentation Style 
 All participants during baseline questioning (Form 1, question 16, 
Appendix E) responded to the question:  
Side effects can be communicated to patients by listing them, with the 
option of adding numbers that represent the percentage of people who 
experience a particular side effect. For example, a pharmacist or doctor 
could say: “The most common side effects are stomach ache, back ache, 
and drowsiness.” Or they could say: “The most common side effects are 
stomach ache (12%), back ache (6%), and drowsiness (2%).” Which 
approach, if any, do you prefer?  
 
They had three options: 1) just the side effects, 2) the side effects and the 
percentages), or 3) no preference. Nineteen (63.3 percent) were interested in 
seeing the percentages for side effects, whereas 10 participants (33.3 percent) 
were interested just in the name of side effects. One participant did not have 
any preference (3.3 percent) (see Table 4.17). 
 
Table 4.17 Preferred presentation of side effects before Study 1 
Preferred presentation  Frequency Percent 
Side effects only 10 33.3 
Side effects plus percentages 19 63.3 
No preference 1  3.3 
Total 30 100 
 
 Later in Study 1, participants responded to a question (Form 8 of 
Appendix J) which asked them about those same preferences for presentation 
of side effects: 
 
 
73
 From what you read [i.e. side effects with and without percentages], 
which explanation would YOU prefer to be given on medication side 
effects? Check ONE of the following options: The first version (a list of 
possible side effects), the second version (a list of possible side effects 
plus the percentages that they may occur), or No preference 
 
Their choices indicate that 83.3 percent (N=25) preferred side effects with 
percentages and their frequency of occurrences, whereas 16.7 percent (N=5) of 
participants still preferred to see the list of side effects only (see Table 4.18). 
 
Table 4.18 Preferred presentation of side effects after Study 1 
Preferred Presentation Frequency Percent 
Side effects only 5 16.7 
Side effects plus percentages 25 83.3 
No preference 0 0 
Total 30 100 
 
 Figure 4.3 compares participant preference for side effect presentation 
style at baseline with their preferences after Study 1. Six participants preferred 
to receive numerical data after doing Study 1, a 20.0 percent increase. 
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Figure 4.3 Participant responses to presentation styles at baseline and after 
Study 1 
 
4.7.6. Effect of Gender on the Likelihood of Taking Drug X, Y, and Z 
The effect of gender was analyzed using Doubly MANOVA to investigate 
whether a main effect of gender, disregarding the headache scenarios, existed 
for the likelihood of taking the three hypothetical drugs with and without 
providing percentages for side effects. If this data were analyzed within the two 
headache scenarios – in which gender would be a third IV to be included in the 
MANOVA – there would be greater need for more participants to give the test 
enough power to find significance without committing type I or II errors. 
Therefore, a safe conclusion could not be drawn on whether gender was a main 
effect when comparing it within the headache scenario simultaneously. The 
severity of headache factor was therefore eliminated in order to achieve enough 
stochastic power to test for a gender effect. Table 4.19 shows the means for the 
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 likelihood of taking the three drugs with and without percentages for side effects 
for female and male participants.  
 
Table 4.19 Effect of gender on mean likelihood of taking Drug X, Y, and Z 
with and without side effect percentages  
Gender 
Male (N=11) Female (N=19)  Drug Presentation of Side Effects 
Mean* ± SD Mean* ± SD 
Total 
N=30 
Without percentages 30.3 ± 16.5 53.5 ± 29.6 45.0 ± 27.7 
Drug X 
With percentages 41.0 ± 28.4 56.5 ± 26.6 50.8 ± 27.9 
Without percentages 53.4 ± 26.1 38.7 ± 30.5 44.1 ± 29.4 
Drug Y 
With percentages 39.9 ± 19.5 40.2 ± 34.6 40.1 ± 29.6 
Without percentages 47.1 ± 34.2 34.6 ± 35.0 39.2 ± 34.6 
Drug Z 
With percentages 52.9 ± 36.6 48.3 ± 40.2 50.0 ± 38.4 
*Likelihood of taking drugs on a 1-100 scale 
 
Figure 4.4 graphically compares female and male participant mean 
likelihood of taking drugs with and without percentages. After receiving 
numerical data for side effects, females showed an increase in mean likelihood 
of taking all three drugs, but Drug X had the highest mean likelihood (56.5). 
Male participant mean likelihood of taking Drug X and Z increased after 
receiving numerical data. However, there was a decrease in likelihood of taking 
Drug Y for male participants. Data shows that Drug Y had the highest mean 
likelihood (53.4) when side effects were presented without percentages, while 
Drug Z had the highest mean (52.9) when side effects were presented with 
percentages. This could mean males switched their preferences to a more 
effective drug (which caries more side effects) after receiving frequency data. 
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Figure 4.4 Effect of gender on mean likelihood of taking Drug X, Y and Z with 
and without percentages for side effects 
 
After eliminating the headache severity grouping factor (mild versus 
severe), some data did not meet the assumptions of MANOVA. For example, 
unequal covariance matrices across the groups (gender) (Table 4.20) and 
unequal error of variance (Levene’s test) existed in some data (Table 4.22). 
Although these assumptions were not met by some of the data, MANOVA is a 
robust test against violations of the homogeneity assumption106 and, therefore, 
was still employed to determine if there were any main effect of gender and any 
significant interaction between the provision of percentages and gender (Table 
4.21). Results of the Doubly MANOVA test showed no significant differences 
with regard to the gender factor (F (3, 26) = 1.917; p>0.05). There was also no 
significant interaction of gender by provision of the side effects percentages 
factor (F (3, 26) = 1.073; p>0.05). However, Table 4.21 also showed there was 
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 a significant difference for mean likelihood of taking Drug X, Y, and Z when side 
effects were presented without and with percentages (F (3, 26) = 3.854; 
p<0.05), which was also reported in Table 4.11. 
 
Table 4.20 Box's test of equality of covariance matrices  
 considering gender 
Box's M 47.026
F 1.642
df1 21
df2 1614.135
Sig. .034
Tests the null hypothesis that the observed covariance matrices of the  
dependent variables are equal across groups  
 
Table 4.21 Multivariate test of variances for effect of gender and provision of 
side effect percentages 
Effect  F df Error df Sig. 
Between-Subjects Gender 1.917 3 26 .152  
Within-Subjects Without vs With percentages 3.854 3 26 .021* 
Within-Between Without vs With by gender 1.073 3 26 .378  
*Sig p<0.05 
 
Table 4.22 Levene's test of equality of error variances considering gender 
F df1 df2 Sig. 
Drug X without percentages 4.425 1 28 .045 
Drug X with percentages .025 1 28 .874 
Drug Y without percentages .980 1 28 .331 
Drug Y with percentages 21.801 1 28 .000 
Drug Z without percentages .086 1 28 .771 
Drug Z with percentages .677 1 28 .418 
Tests the null hypothesis that the error variance of the dependent variable is equal across 
groups 
 
 
 
78
  The test of between-subject effects (Table 4.23) showed there was a 
significant difference between the mean likelihood of taking Drug X when 
comparing males with females (F (1, 28) = 5.366; p<0.05), but there was no 
significant differences between females and males regarding their mean 
likelihood of taking Drug Y (F (1, 28) = 0.509; p>0.05) or Drug Z (F (1, 28) = 
0.614; p>0.05). This means female participants were more likely to use Drug X. 
 
Table 4.23 Tests of between-subjects effects of gender variable on  
 Drug X, Y, and Z 
Source Measure df Error df F Sig. 
Drug X 1 28 5.366 .028* 
Drug Y 1 28 .509 .482  Gender 
Drug Z 1 28 .614 .440  
*Sig p<0.05 
 
4.7.7. Effect of Previous Experience with Side Effects on the Likelihood of 
Taking Drug X, Y, and Z  
The effect of previous experience with side effects was examined on the 
likelihood of taking the three hypothetical drugs with and without providing 
percentages for side effects using Doubly MANOVA. In order to detect a main 
effect of previous experience, it was necessary to disregard the headache 
scenario factor for the same reason as mentioned in section 4.7.6. After 
eliminating this grouping factor, and looking at previous experience with the 
side effects factor, the data met all assumptions for Doubly MANOVA. 
Table 4.24 shows the mean likelihood of taking Drug X, Y and Z with and 
without providing percentages for side effects for the two groups of participants 
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 who previously experienced any side effects (defined by Yes = had experienced 
and No = had not experienced).  
 
Table 4.24 Effect of previous experience with side effects on mean likelihood 
of taking Drug X, Y, and Z with and without side effect 
percentages 
Previous Experience with Side 
Effects 
Yes (N=11) No (N=19) Drug 
Presentation of 
Side Effects 
Mean* ± SD Mean* ± SD 
Total 
N=30 
Without percentages 47.5 ± 29.5 43.5 ± 27.3 45.0 ± 27.7 
Drug X 
With percentages 53.8 ± 30.4 49.0 ± 27.0 50.8 ± 27.9 
Without percentages 35.5 ± 35.0 49.1 ± 25.3 44.1 ± 29.4 
Drug Y 
With percentages 25.6 ± 30.0 48.5 ± 26.6 40.1 ± 29.6 
Without percentages 28.2 ± 31.4 45.6 ± 35.6 39.2 ± 34.6 
Drug Z 
With percentages 38.9 ± 42.3 56.4 ± 35.5 50.0 ± 38.4 
* Likelihood of taking drugs on a 1-100 scale 
 
The result showed no significant difference between groups who had 
experienced side effects in the past and those who hadn’t (F (3, 26) = 1.342; 
p>0.05). There was also no significant interaction between with versus without 
percentages by previous experience with side effects (F (3, 26) = 0.298; 
p>0.05). Test of the within-subject factor (as reported in previous sections) 
showed a significant difference (F (3, 26) = 3.408; p<0.05) in comparing the 
with versus without side effect percentages factor on the mean likelihood of 
taking Drug X, Y and Z (see Table 4.25). 
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 Table 4.25 Multivariate test of variances examining participants previous 
experience with side effects, provision of side effect percentages 
Effect F df Error df Sig. 
Between-Subjects Previous experience with side effect 1.342 3 26 .282 
Within-Subjects Without vs With percentages  3.408 3 26 .032* 
Within-Between Without vs With by previous side effect experience  .298 3 26 .826 
*Sig p<0.05 
 
There were no significant differences in mean likelihood of taking Drug X (F (1, 
28) = 0.234; p>0.05), Drug Y (F (1, 28) = 3.598; p>0.05), or Drug Z (F (1, 28) = 
2.739; p>0.05) for the two groups of participants who had or hadn’t experienced 
any side effects. Table 4.26 shows the test of between-subjects effect of 
previous experience with side effects on each drug. 
 
Table 4.26 Tests of between-subjects effect of previous experience with side 
effect variables on Drug X, Y, and Z 
Source Measure df Error df F Sig. 
Drug X 1 28 .234 .633 
Drug Y 1 28 3.593 .068 Previous experience with side effects 
Drug Z 1 28 2.739 .109 
 
4.7.8. Effect of Gender on Preferred Drugs  
Pearson Chi-Square tests were used in order to determine if participant 
choices of drugs were different between females and males (for the two 
presentation styles of with and without percentages). Pearson Chi-Square 
showed no significant differences among females and males on their choices to 
take a drug across both presentation styles (without and with percentages for 
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 side effects (χ2 (3) = 2.929; p>0.05) and (χ2 (3) = 5.533; p>0.05), respectively) 
(see Table 4.27). 
 
Table 4.27  Effect of gender on drug choices 
Gender 
 Preferred drug Male Female  Total 
Drug X 2 8 10 
Drug Y 4 3 7 
Drug Z 4 5 9 
None 1 3 4 
Without 
percentages 
Total 11 19 30 
Drug X 3 8 11 
Drug Y 0 4 4 
Drug Z 7 7 14 
None 1 0 1 
With 
percentages 
Total 11 19 30 
 
4.8. Study 2: Effect of Negatively- or Positively-Slanted Presentation of 
Side Effects 
In the second study, the mean likelihood of taking two hypothetical drugs 
(Drug P and N) were compared to investigate whether or not presenting side 
effects in positively- or negatively-slanted wording would have an effect on their 
likelihood of taking those medicines. All 30 participants considered both Drugs 
P (standing for Positively-slanted) and Drug N (standing for Negatively-slanted) 
and were asked to express their likelihood of taking them on a scale of 1 (very 
unlikely) to 100 (very likely). To control for the effect of presentation order, half 
of participants received Drug P first and the other half received Drug N first. 
Table 4.28 shows the mean likelihood of taking Drugs P and N.  
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 Table 4.28 Likelihood of taking Drug P and N 
Drug Drug order N Mean* ± SD Std. Error 
Drug N first, Drug P second 15 53.1 ± 26.3 6.78 
Drug P first, Drug N second 15 67.1 ± 23.3 6.02 Drug N  
Total 30 60.1 ± 25.4 4.64 
Drug N first, Drug P second 15 70.5 ± 21.4 5.52 
Drug P first, Drug N second 15 79.9 ± 15.0 3.88 Drug P  
Total 30 75.2 ± 18.8 3.43 
* Likelihood of taking drugs on a 1-100 scale 
 
Independent sample t-test showed no difference between the mean 
likelihood of taking Drug P (t (28) = 1.393; p>0.05) and Drug N (t (28) = 1.551; 
p>0.05) for participants receiving the drugs in the different order. Therefore, the 
presentation order did not significantly affect the measure of likelihood. 
After discounting the possible influence of the order of presentation, a 
Paired sample t-test was carried out to compare the mean likelihood of taking 
Drug P (with the side effect expressed as 90% will not experience heartburn) 
with Drug N (with the side effect expressed as 10% will experience heartburn). 
Results of the t-test (see Table 4.29) showed that the likelihood of taking Drug 
P (positive-slant) was significantly greater than the likelihood of taking Drug N 
(negative-slant) (t (29) = 3.558; p<0.05) (see Figure 4.5) 
 
Table 4.29 Paired sample t-test comparing mean likelihood of taking Drug P 
and N 
Paired Differences 
  Mean ± SD Std. Error 
t df Sig.  
Drug P vs Drug N 15.1 ± 23.3 4.253 3.558 29 .001* 
*Sig p<0.05 
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Figure 4.5  Likelihood of taking Drug P and N 
 
Participants were asked which they would prefer to use if they had a 
headache; the choices were Drug P, Drug N, Equally, or Neither Agent. Sixty 
percent (N=18) of the participants agreed with the statement – I would prefer 
the two agents equally – whereas 30 percent (N=9) preferred Drug P, 10 
percent (N=3) were not interested in any drug, and no one chose Drug N. 
When asked to choose which presentation style for side effects they 
preferred, participants slightly preferred the statement – 90% will not get 
heartburn – (56.7 percent) compared to the statement – 10% will get heartburn 
– (chosen by 43.3 percent). 
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 4.8.1. Effect of Gender on the Likelihood of Taking Drug P and N 
Factorial ANOVA (two-way ANOVA) was run to compare the likelihood of 
taking Drug P and N for females versus males. Table 4.30 shows the overall 
mean likelihood for Drug P and N considering the gender factor. The data, 
divided by the gender factor, did not meet the assumption of homogeneity of 
variance for the ANOVA test (Table 4.31), but the test is robust against 
violations of the homogeneity assumption. Therefore, it was used to examine if 
there was any significant effect of gender. 
 
Table 4.30 Mean likelihood of taking Drug P and N based on gender 
Gender Drug N Mean* ± SD Std. Error 
Male 11 70.6 ± 13.6 4.1 
Female 19 77.9 ± 21.1 4.8 Drug P  
Total 30 75.2 ± 18.8 3.4 
Male 11 62.9 ± 19.9 5.9 
Female 19 58.5 ± 28.6 6.5 Drug N 
Total 30 60.1 ± 25.4 4.6 
* Likelihood of taking drugs on a 1-100 scale 
 
Table 4.31 Levene's test of equality of error variances  
 considering gender 
Drug F df1 df2 Sig. 
Drug P 2.876 1 28 .101 
Drug N 5.894 1 28 .022 
 
Results showed there was no significant difference between females and 
males regarding their mean likelihood of taking either Drug P or Drug N (F (1, 
28) = 0.037; p>0.05). There was also no interaction of gender by mean 
likelihood of taking Drug P and Drug N (F (1, 28) = 1.804; p>0.05) (see Table 
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 4.32). However, the within-subject test comparing the mean likelihood of taking 
Drug P and Drug N showed a significant difference (F (1, 28) = 9.726; p<0.05), 
even after adding the gender factor to the data (see Table 4.32).  
 
Table 4.32  Effect of gender on Drug P and N 
Tests Effect F df Error df Sig. 
Between-Subject Gender 0.037 1 28 .849  
Within-Subject Drug P vs Drug N 9.726 1 28  .004* 
Between-Within Drugs by Gender  1.804 1 28 .190  
*Sig p<0.05 
 
4.8.2. Effect of Previous Experience with Side Effects on the Likelihood of 
Taking Drug P and N 
Factorial ANOVA (two-way ANOVA) was used to determine the effect of 
previous experience with side effects on the mean likelihood of taking Drug P 
and Drug N. Table 4.33 shows the mean likelihood of taking Drug P and N 
between the two groups of participants in relation to previous experience with a 
side effect (defined by Yes = had experienced and No = had not experienced). 
 
Table 4.33 Mean likelihood of taking Drug P and N considering  
 previous experience with side effects  
 
* Likelihood of taking drugs on a 1-100 scale 
Drugs Previous experience N Mean* ± SD Std. Error 
Yes 11 74.3 ± 18.1 5.5 
No 19 75.8 ± 19.6 4.5 Drug P 
Total 30 75.2 ± 18.8 3.4 
Yes 11 52.6 ± 24.6 7.4 
No 19 64.4 ± 25.5 5.8 Drug N 
Total 30 60.1 ± 25.4 4.6 
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 Two-way ANOVA showed no significant differences between the two 
groups (Yes and No) regarding to their likelihood of taking Drug P and N (F (1, 
28) = 0.841; p>0.05). There was also no significant interaction of the mean 
likelihood of taking Drug P and N with previous experience with the side effects 
factor (F (1, 28) = 1.371; p>0.05). However, the within-subject test comparing 
the mean likelihood of taking Drug P and Drug N showed a significant 
difference (F (1, 28) = 14.165; p<0.01), even after adding the previous 
experience with side effect factor to the data (see Table 4.34). 
 
Table 4.34  Effect of previous experience with side effects on mean likelihood 
of taking Drug P and N 
Tests Effect F df Error df Sig. 
Between-Subject Previous experience with side effects .841 1 28 .367 
Within-Subject Drug P vs Drug N 14.165 1 28 .001* 
Between-Within Drugs by previous experience with side effects 1.371 1 28 .252 
*Sig p<0.05 
 
4.9. Interview Highlights 
 While the interviews represent qualitative data, the approach to analysis 
was not to undertake numerous iterations to uncover exacting themes as is 
typical for qualitative research. Rather, these interviews were done to provide 
greater depth in how respondents approached their decision-making. To attain 
this goal, the researcher asked for their thoughts in relation to the position they 
took using the research questions as a guide. In the pharmacy literature, this 
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 does not appear to be common practice. Instead, methodologies tend to follow 
one (survey) or the other (interview) approaches.  
 
4.9.1. Personal Experience with Side Effects 
 Participant past experience with medicine side effects could impact 
decisions on using another medication in the future. Of note is that few 
participants described having previous experience with any of the side effects 
listed for drugs of the study. Some had encountered other effects not listed. The 
nature of that side effect history had little effect on the propensity to take any of 
the drugs presented. However, the interviews uncovered some concern that for 
some, affected their decision-making process:  
And this one here causes nausea, rash, dizziness, heartburn, diarrhoea, 
dry eyes – I mean like why would I want to take this one [pointing to Drug 
Z]? I wouldn’t if they have all that. I can handle a little nausea … 
diarrhoea I can’t because I suffer from colitis and I get it enough anyway, 
so I don’t want to take a pill that’s going to give it to me more. Many 
years ago, I have taken pills that gave me every one of these … well not 
about heartburn … everything else – I get dry eyes. Some places neglect 
to put on dry mouth because that generally happens more than dry eyes. 
[Interview 7] 
 
I took the one pill I had – you couldn’t believe the side effects on it. It was 
for an arthritis pill – Methotrexate. I mean, I’m lucky my hair is even here 
– my hair would come out, just fell out. And yet, it was a very low 
percentage of hair loss but that affected me worse than anything … 
when my hair started falling out in globs. I went back and I said you know 
what I’d rather be in pain than be bald. [Interview 7] 
 
It kind of depends on what the side effects are. I mean dizziness, 
nausea, that’s prevents you from doing your job as much as the 
headache – it’s a headache type thing – so I would say it kind of 
depends on what the of side effects are. If it’s a dry cough, every so 
often, that doesn’t stop you from doing your job – or if it’s – whatever 
some of the other side effects may be, like a rash, that could be treated 
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 with something else. But I like the drugs to be effective and stop the pain, 
for example, if it’s pain medication. But you don’t want some bizarre side 
effects though either. [Interview 29] 
 
4.9.2. Impressions of Taking Too Many Medications 
 Much like having to deal with side effects in the past, some participants’ 
current use of medications probably affected their decision to use another 
medication for a headache. It would surely be the rare person who would enjoy 
adding another agent to their day. As such, such hesitancy would come into 
play in their real worlds, as it could during this study: 
With the medication I’m taking, there is very little that I can take for pain, 
except for Tylenol. So I guess I kind of put my own experience in there. 
[Interview 4] 
 
I take a lot of drugs – and I will only take – if it bothers me. I mean it 
drives my doctor crazy sometimes but I’m just not taking it. There must 
be something better out there and if you keep on, they will find you 
something better. They might get annoyed at you, but they will find 
something better. I go to an arthritis specialist because I have arthritis 
and I have to go back over and over. [Interview 7] 
 
The side effect information was processed quite methodically by one 
participant who had to deal with a few medications in his own life. The following 
is his reasoning for choosing Drug Z: 
I tend to be lucky with those things and not fall into the category that gets 
hammered by side effects. Usually I have a very solid stomach so 
nausea is something that rarely ever occurs in me. Then I look at rash – I 
have rash all the time so … because of other medications I take. So that 
wouldn’t affect me or that wouldn’t affect my decision. And then dizziness 
– I rarely ever get dizzy. I used to when my diabetes wasn’t in control but 
that’s over. So then heartburn – I very rarely have that. I have high 
acidity, but I have drugs to deal with that. Diarrhoea occurs only with one 
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 medication that I take in combination with certain foods, so I have that in 
control. All those side effects that you mentioned are in control with me 
and the likelihood that they would occur with this sample drug would be 
low. [Interview 23] 
 
4.9.3. Role of Numerical Data and Its Effect 
 The impact of presenting side effect frequency in numerical form was 
explored in the interviews. Participant likelihood of taking the medications 
increased subsequent to the numerical information they received. Some 
examples of how participants processed the information before (and after) 
seeing the percentages are included in this section: 
I think probably because of some of the side effects – when I first looked 
at it, I was a little concerned about what my activities might be after I took 
Drug Z and I didn’t want to, say, be caught in a bad position if I did 
develop diarrhoea … that I wanted to be somewhere close to a bathroom 
or something like … I didn’t want to be driving a car down the highway or 
something like that. That was kind of my main concern with picking Drug 
Y over Drug Z … is the possible side effects when I’m doing some other 
activities. [Interview 6] 
 
 With numerical data appearing, participant likelihood to take an agent 
generally increased. For some, it persuaded them to switch to a more effective 
drug (accompanied by more side effects): 
As I said before, I was concerned about the diarrhoea but when I see it 
… the diarrhoea is only a 2% chance of developing it. That’s a pretty 
good risk to take and you are not going to get it. [Interview 6] 
Because I looked at the percentages and some of them are very low for 
… for some of the side effects … more debilitating perhaps. This just lists 
the consequences or the possible side effects. And this one [Form 7] 
shows the approximate percentages, which are not that high for the 
 
 
90
 diarrhoea and dry eyes, which are the ones that are added from the 
others. And it was faster and more effective. [Interview 8] 
 
The second one gives the percentages and I think the first one seemed 
simpler in a way. It didn’t require thinking about percentages and I 
thought Drug Y – I guess it was, yeah, 75% effective. I choose it because 
there was no mention of diarrhoea and I thought Drug Z with diarrhoea 
would be, could be anyway, fairly severe. So that was my reasoning 
there. Then looking at the percentages in form seven, they are quite low 
anyway, so that’s why I moved up to Drug Z to the one actually I prefer 
because the percentages of rash or diarrhoea is less than 1% and so on. 
So it seemed very minimal, so it was worth the risk. [Interview 10] 
 
So my main objective was to do whatever would be most likely to help 
me feel better, so I could do what I have to do. That’s why I went for the 
one that was the least likely to have the side effects. It would depend on 
how crucial the deadline is because if it was really really crucial, I might 
have thought of taking the 100% one and risk the side effects. But if it’s 
not so crucial, then I’m not willing to risk those side effects. It turned 
around here [After numerical data] because I was given the percentages, 
I could see they were very low. And the first one, I wasn’t given the 
percentages to tell me how likely those side effects were. And when I 
saw they were very low, I thought well then, I’ll take the one that’s most 
likely to be effective because that’s very low percent of chance that I’ll 
get those side effects. [Interview 5] 
 
The side effects do not look that high. The highest side effect was 7% 
and I guess I would be watching to see if I experience some dizziness or 
some heartburn … or I guess any of these side effects. But the two 
[critical one] I’d be looking at mostly is the dizziness and the heartburn. 
[Interview 22] 
 
One participant thought the numerical data added unnecessary clutter to 
the reading materials: 
I had originally said that I thought the percentages would … What I saw 
when I read it was it somehow made the information more … and made 
me less likely to read it because it was more so … I think that’s why it 
actually didn’t change. But in both cases, I felt that two side effects is far 
better than three or four or five and that’s why I stayed with X on both of 
them. And it is because it [Drug X] had less potential side effects. I think 
in a way it was feeling like … because I know that I’m a healthy person 
and I don’t usually get side effects. Seeing two side effects, you are 
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 feeling very confident with that. When I go down to Z, for example, I think 
there’s five of them here, you begin to think though, the law of average 
says I’m going to get one of them. [Interview 9] 
 
4.9.4. Illness Severity and Importance of Drug Effectiveness  
 Participant choice for a drug depended on which headache scenario they 
received. Here are two participant statements on how they decided to use a 
medicine: 
Mild headache scenario – My feeling was that even though Drug X was 
the least effective, it also had the least side effects. So I was prepared to 
wait a little longer or have even just a little reduction in pain as opposed 
to … maybe if I was somebody who actually suffered from migraines, I 
might have felt differently. [Interview 9] 
 
Severe headache scenario – Well, because it [Drug Z] was 100% 
effective. I know it has a lot of side effects, but it probably doesn’t affect 
everyone that way. So that’s why I picked that one. [Interview 2] 
 
4.9.5. Side Effects versus Effectiveness 
 Participant decisions toward selecting a medicine evoked different takes 
on attributes. For some, effectiveness was more of a concern while for others, it 
was side effects. The majority, however, felt their decisions were influenced by 
both. The following examples reveal how people might weigh a drug’s benefits 
versus its’ risks:  
The side effect information was more influential in choosing Drug X 
because it has a lower … 3% … 4% … and well, nausea, rash not that 
bad – it’s a headache – dizziness at 7% – when you are taking a 
medication to get rid of headaches. But it’s still going to cause dizziness 
so therefore, you know, 7% … I rounded it up to 10 again, and that’s 
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 pretty major. So that it was definitely the percentages of the side effects 
that caused me to choose Drug X. [Interview 29] 
 
I think it would be side effects …in the first form [Form 6] … because it 
says it may cause nausea or rash. But no mention of how lightly – 
whereas form seven says how lightly and it seemed like a small … like 
the odds are small. So I’d rather have the 100% effective … given the 
small odds of the side effects. [Interview 10] 
 
So that’s why I picked it here [Drug Z in Form 7] and changed [my 
choice] from 75% [effectiveness] because this one here says – it gives 
you the same. This one gives you nausea, rash, dizziness and heartburn 
and no diarrhoea or dry eyes – I never have problems with that. So I 
simply decided from the point of view of mathematical probability – I 
won’t probably be one of those affected. And I would take it. But I’m 
always thinking that when I give you an answer like that, that I have a 
choice to go back to Y or X. After this goes on … won’t kill me. You don’t 
say as a side effect as killing. You have no idea how many times I read 
about drugs which have sudden death as a side effect, so if that’s not in 
there, then I’m fine. [Interview 23] 
 
4.9.6. Effect of Negatively- versus Positively-Slanted Wording 
 Probing was undertaken for participants who showed more than 10 
points (on the scale) in favour of using Drug P over Drug N. Some explanation 
for this finding is as follows: 
I think it’s in the way it was phrased – one is I have a 10% chance of 
getting it … sounds so much more than when you say 90% of people 
don’t. I can easily … for some reason … it sounds … but maybe I just 
like things phrased positively. But yeah, I felt that even though I know it’s 
the very same thing, that 90% not getting it sounds somehow less scary 
than 10% getting it. [Interview 9] 
 
Yeah, I started out with – 90% will not experience heartburn, I think it’s a 
psychological difference. I’m assuming I would be among the 90, I think, 
that would not experience heartburn, so I feel comfortable with that.  
Drug N, on the other hand, says 10 out of 100 ‘will’ experience 
heartburn, which seems like a very positive … like it’s very … if the word 
was ‘might’ experience heartburn, I would feel more comfortable with that 
drug. But it says 10 out of 100 will experience heartburn, so that moves it 
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 down in my preference list. See this one … on the flip side … will not 
experience … it doesn’t say that the other ten … they may be in that 
group as well. Now, if it went on to say – will not experience heartburn, 
however ten will, then I would put them on an equal playing. [Interview 
10] 
 
Well, I suffer from heartburn, so I thought if this one … it says will not 
experience heartburn and this one will experience heartburn, so that’s 
why I went with this one instead of that one, because I hate heartburn. 
[Interview 2] 
 
4.10. Summary of Interviews 
 Interview data support the finding of the main results. Participants were 
more likely to use their medicine with inclusion of numerical data to the 
medication side effects. This was the first finding of the study and participant 
opinions during the interviews reveal a similar pattern. Regarding the 
importance of illness severity in choice of medication, as headache severity 
rises, people chose more effective remedies in spite of side effect potential. 
Participant interviews confirmed that seeking a more effective drug would be 
considered when experiencing a severe headache. The interviews revealed 
both side effects and effectiveness of a medicine play an important role, but 
severity and risks were of equal importance in their decision; all these 
influences affected their decision. Some articulated that the probability of 
experiencing any of the side effects was acceptable, further enhanced by the 
fact they were not perceived as all that severe. On the issue of positively- and 
negatively-slanted framing, interviews of just those who felt Drugs N and P 
presented different risk confirmed that experiencing heartburn was less likely to 
happen when they received positive framing. 
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 CHAPTER 5 
DISCUSSION  
Patients increasingly face a bewildering array of health risks. Deciding 
which risks are important for patients to attend to is difficult – but it matters. 
Inaccurate risk perceptions have important consequences. If people at high risk 
for diseases are unaware of their elevated risk, they may fail to appropriately 
consider interventions that might be beneficial. If those at low risk for diseases 
have a falsely heightened sense of risk, they may experience undue anxiety 
and may pursue interventions that offer them more harm than benefit. 
Understanding the magnitude of a health risk is fundamental to deciding 
whether the risk is acceptable and, if so, whether to consider taking some 
action to reduce the risk. 
In the field of pharmaceutical care, drug information on labels and inserts 
is a major source of knowledge for patients as they attempt to balance the risks 
and benefits of drugs and administer them safely. However, this information is 
often inconsistent, incomplete, and difficult for patients to read and understand. 
The fact is it is not easy to present a single best approach for conveying a 
medication’s adverse effects to individuals. This is true for all medication, but 
may especially be true for medicines available without prescription. For this 
reason, this study was undertaken. 
Thirty subjects 50 years of age and up from Saskatoon participated, with 
an average age of approximately 67 years. Of those, 63.3 percent were female 
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 which, for comparison purposes, appears to be slightly (8.2 percent) more than 
the city population (based on Community Profiles from the 2006 Statistics 
Canada Census107). Less than half of participants (n=11) had previous 
experience with side effects. Most participants (90 percent) were using at least 
one medicine (be it OTC or Rx or both) and described their knowledge as 
knowledgeable or somewhat knowledgeable. On the BMQ, subjects tended not 
to perceive medicines as harmful, but showed some uncertainty as to whether 
physicians overused them.  
To gauge how well people in this study understood medical information, 
a measure was used to quantify their numerical skill.20,62. Six questions which 
were most relevant to this study were chosen (four questions related to Study 1 
and two related to Study 2). Forty percent of participants answered three to four 
questions correctly, 50 percent answered one to two, and 10 percent failed to 
provide a correct answer to any question. This shows that almost 60 percent of 
our participants struggled to solve basic numerical questions, despite the fact 
that about 50 percent of the participants had a university degree and 33.3 
percent had a high school or technical diploma.  
 Headaches are a very common complaint for consumers100 and this 
helps explain why analgesics are a large category in the OTC market. The 
study created hypothetical scenarios in which a person was asked to decide on 
a painkiller for relieving headache. Differing levels of headache severity were 
utilized because illness severity may be an issue in participant choice. This set 
in motion a situation requiring the balancing of risk-benefit information during a 
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 decision-making process where different choices were available. More 
importantly, assessing the impact of providing numerical data for side effect 
occurrence was possible. In other words, would the propensity to take Drug X 
(just by way of example) change with the provision of numerical side effect 
data? Would subjects be more or less willing to take it (or any of the others) 
upon seeing the numerical data? Then, might subjects change their overall 
decision, perhaps from a drug of low efficacy and minimal side effects, to one of 
higher efficacy and more side effects, if provided that same numerical side 
effect data? 
Thirty participants were given the option of three hypothetical OTC 
medicines, all of which had differing efficacy and differing numbers of side 
effects. The three drugs available for selection were fictitious (Drug X, Y and Z) 
and were described as 50, 75, and 100 percent effective, while exhibiting two, 
four, and six side effects, respectively. While side effects were the focus of the 
study, a measure of effectiveness was needed in the design. The reason for 
this is that increasing the number of side effects attributed to the three drugs 
had to be offset by how well the agent might treat a headache (aka 
“effectiveness”). Otherwise, subjects would have balked at selecting a drug with 
more side effects if it possessed the same potential for relief. Another 
methodological issue was drug nomenclature. Choosing agents that did not 
exist in the market place removed the direct effect of personal experience from 
the decision-making process. Because side effects were presented, first without 
percentages and then with percentages, instant feedback could be obtained 
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 with minimal influence from external factors. This simultaneity allowed a better 
determination of patient preference of a drug (or the likelihood of taking a 
certain medicine) when the provision of frequency of side effects was the only 
factor. 
The results (Table 4.10) show the mean likelihood (scale 1 to 100) of 
taking Drug X was 50.2 before seeing side effect frequencies, then moved to 
62.6 (on the same scale) after seeing the numerical side effect data. This 
applied to the mild headache scenario. For the severe headache scenario, for 
Drug Z, the mean likelihood value went from 41.3 before seeing the 
percentages to 64.7 after seeing the percentages. However, only the change 
seen for Drug Z was significant. The values for Drug Y showed the opposite 
trend. This shows that when the headache was severe, the effectiveness of 
medication becomes more important to participants than side effects. But 
providing numerical data for side effects also increased participant likelihood of 
using Drug Z and since some participants switched their choice from Drug Y to 
Drug Z (in the severe headache group), their mean likelihood of taking the 
chosen drugs went up for Drug Z and down for Drug Y. This was seen as a 
reason why there was a decrease in the mean likelihood of choosing Drug Y. It 
was also possible that the low percentages of alarming side effects (diarrhoea 
and dry eyes) were a reason to make participants comfortable in switching to a 
more effective drug.  
Given the fact there were two headache scenarios, limited sample size, 
and a need to consider changes across all three drug choices simultaneously, 
 
 
98
 more complex analyses were required. Doubly Multivariate ANOVA allowed a 
comparison of two headache groups (mild and severe) and side effect 
frequency data (with and without percentages) at the same time. When taken 
as a whole, the results showed a significant increase in the mean likelihood of 
taking all three agents (Drug X, Y and Z) subsequent to receiving numerical 
data. This suggests that providing numerical data instilled some sense of relief, 
to be confident in choosing a medicine that works and not be alarmed by the 
level of risk (once perspectives on occurrence were added).  
When looking at the mean likelihoods (with and without percentages 
together) for the three medicines, there was no difference between the mild 
versus severe headache group. In the severe headache scenario, it appeared 
that respondents were not interested in Drug X because at only 50% effective, it 
would not be strong enough for severe headaches. People wanted relief, so the 
choices largely came down to either Drug Y or Z. Their first choice for severe 
headaches was in fact Drug Y before seeing side effect percentages. After 
seeing the numerical data, most changed their selection to Drug Z. Before 
percentages, what seemed to be the issue between Drug Y and Drug Z was 
that the new side effects – diarrhoea and dry eyes – may have scared people 
away from Drug Z. It appeared that after they saw the percentages, the 
frequency values attached to those problematic side effects led to less alarm, 
thus allowing a switch to Drug Z with more confidence. This was articulated by 
the following participants: 
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 When I first looked at it, I was a little concerned about what my activities 
might be after I took Drug Z and I didn’t want to say be caught in a bad 
position if I did develop diarrhoea … that I wanted to be somewhere 
close to a bathroom or something like – that was kind of my main 
concern with picking Drug Y over Drug Z … I was concerned about the 
diarrhoea. But when I see it [Form 7], the diarrhoea is only a 2% chance 
of developing it, that’s a pretty good risk to take and you are not going to 
get it. [Interview 6]  
 
I thought Drug Y … I guess it was, yeah, 75% effective. I choose it 
because there was no mention of diarrhoea and I thought Drug Z with 
diarrhoea would be, could be anyway, fairly severe. Then looking at the 
percentages in Form 7, they are quite low anyway, so that’s why I moved 
up to Drug Z to the one actually I prefer … because the percentages of 
rash or diarrhoea is less than 1%. It seemed very minimal, so it was 
worth the risk. [Interview 10] 
 
In the mild headache scenario, Drug Y was rarely considered; Drug X 
was largely perceived as the better option. People were very pragmatic – it was 
still considered somewhat effective, but if it did not work for them (in real life), 
they could easily move on to a stronger agent in a day or so. For that level of 
headache, though, there seemed to be low tolerance for side effects, thus they 
chose the agent with the least risk. Therefore, numerical frequency data for side 
effects at this juncture had the following effect – to further justify their choice in 
selecting Drug X.  
The percentage figures utilized for the side effects were very close to 
those values seen for actual agents such as acetaminophen and ibuprofen. 
They were selected from product monographs of Advil®, Motrin®, Tylenol®, and 
Aspirin® via Lexi-Comp online and e-CPS (circa 2007). However, participant 
decisions might have been different if higher percentages were attached to the 
given side effects. For example, if the possibility of experiencing dizziness was 
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 17 percent instead of seven, participants may not have considered it at all. The 
choices of side effects selected were also a factor which might have influenced 
decisions on using a medicine. Therefore, if a participant actually suffered from 
dry eyes, even a small chance of getting it might be considered an 
unacceptable risk. By extension, a choice of side effects considered more 
severe (e.g. kidney problems, troubled breathing) by the public would also 
create stronger hesitation towards use.  
Each person was asked to select which style of presentation (with and 
without percentage data) they would prefer. This was in fact done twice. The 
first time was done at the very beginning of the study. The second time 
occurred at a later juncture. This approach was taken to allow participant 
perspectives before exposure to the technical aspects found within this study. 
Thus, preferences would be seen for so-called naïve participants in the 
beginning of the survey, then again later after seeing numerical percentage 
data by the end of the survey. It turned out that most people did not change 
their answers, but six did move from preferring just a list of side effects to then 
welcoming inclusion of frequency data. So, for some, exposure to the study 
process may have increased their interest in numerical data to help with future 
decision-making involving medicines. Of significant interest, though, is that 19 
of 30 wanted this level of information upon arrival at this study. If creators of 
medicine information leaflets are hesitant to include frequency data – out of fear 
for scaring off users, creating information overload, or causing leaflet clutter – 
this may not be the case.  
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 While participants responded to Drug X, Y, and Z on likelihood of use 
and how it might change before and after frequency data, participants were also 
asked to select which of the three they would overall prefer to use (if in real life). 
This was asked twice as well (before and after frequency data). The reason for 
taking this step was because likelihood scales just showed how use might 
change on an individual drug basis, disregarding the other two agents at that 
time. Asking for overall preference forced respondents to outright identify which, 
of the three agents available to them considered concurrently, was most 
desirable. While there was a tendency to use Drug Y (in the severe headache 
scenario), amongst the three drugs before exposure to frequency data (Table 
4.16), seeing the numerical data moved choices more to Drug Z. In the mild 
headache scenario group, Drug X remained the desirable drug before and after 
frequency data were added. This was mainly influenced by illness severity; 
people opted for more effectiveness at a cost of a greater side effect profile 
when the headache was severe. In looking at the data in more detail, of the 30 
decisions made initially, and then made again after the frequency data, 17 did 
not change their drug choice, while nine did (moving to a more effective agent). 
What this suggests is that inclusion of the numerical data did not appear to 
“scare away” potential users. This data also reflects what was seen for the 
mean likelihood data for the individual drugs. Interviews provided some depth 
into how subjects reacted to numerical frequency data: 
 
Because I looked at the percentages and some of them are very low for 
– for some of the side effects more debilitating perhaps – this just lists 
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 the consequences or the possible side effects. And this one [Form 7] 
shows the approximate percentages which are not that high for the 
diarrhoea and dry eyes, which are the ones that are added from the 
others. And it was faster and more effective. [Interview 8] 
 
First I thought I’d take the one most likely to be effective, but then I 
thought, no, because if there is more chance of side effects, then it 
wouldn’t be helpful to get things done. So my main objective was to do 
whatever would be most likely to help me feel better, so I could do what I 
have to do. That’s why I went for the one … that was the least likely to 
have the side effects. It would depend on how crucial the deadline is 
because if it was really really crucial, I might have thought of taking the 
100% one and risk the side effects. But if it’s not so crucial, then I’m not 
willing to risk those side effects. It turned around here [after numerical 
data], because I was given the percentages … I could see they were 
very low. And the first one … I wasn’t given the percentages to tell me 
how likely those side effects were. And when I saw they were very low, I 
thought, well then, I’ll take the one that’s most likely to be effective 
because that’s very low percent of chance that I’ll get those side effects. 
[Interview 5] 
 
 Regarding personal experience with side effects, there was no significant 
effect on participant mean likelihood of selecting the three drugs when 
considering previous experience. This could be due to the small number of 
participants with previous side effects experience. However, six out of 11 
participants (who experienced a side effect before) preferred Drug X to use as a 
painkiller and two decided to take no medicine. This suggests that such 
experience may have made subjects choose Drug X which had the least 
number of side effects. Some issues did arise during the interviews to reflect 
the existence of this factor in the participant’s mindset:  
 
And this one here causes nausea, rash, dizziness, heartburn, diarrhoea, 
dry eyes. I mean, like why would I want to take this one [pointing to drug 
Z]? I wouldn’t because if they have all that ... I can handle a little nausea 
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 … diarrhoea I can’t because I suffer from colitis and I get it enough 
anyway. So I don’t want to take a pill that’s going to give it to me more. 
Many years ago, I have taken pills that gave me every one of these … 
well, not about heartburn … everything else – I get dry eyes. Some 
places neglect to put on dry mouth because that generally happens more 
than dry eyes. I took the one pill I had … you couldn’t believe the side 
effects on it – it was for an arthritis pill – Methotrexate – I mean, I’m lucky 
my hair is even here. My hair would come out, just fell out. And yet, it 
was a very low percentage of hair loss, but that affected me worse than 
anything. When my hair started falling out in globs, I went back and I said 
you know what, I’d rather be in pain than be bald. [Interview 7] 
 
In the above example, suffering from colitis was something that 
eliminated the thought of using Drug Z for this participant. Experiencing all the 
side effects listed for these three drugs made her nervous about getting them 
again. She chose Drug X before and after the provision of numerical data. Of 
course, not all participants fell into this situation. For most participants in this 
study, effectiveness and side effects were the concern before receiving the 
percentages, while effectiveness became more important when the frequency 
data gave them a sense of relief.  
In spite of any significance identified, or even trends in a positive 
direction favouring the inclusion of numerical frequency data, one should be 
cautious about concluding that pharmacists should include frequency data with 
side effect data in practice. More needs to be done for different illnesses and for 
different drugs, and with more severe types of side effects.   
Further support for a cautious approach is the fact that contradictions 
were seen even within data of the current study on how to approach side effect 
information at a broader level. Almost 97 percent of participants strongly agreed 
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 / agreed that they would like to receive information about side effects and that 
they read written information provided by pharmacists. Then, 93.3 percent 
strongly agreed / agreed that pharmacists should give detailed information to all 
individuals regarding mild and rare side effects. However, 86.6 percent then 
strongly agreed / agreed that “side effect information provided to me puts me in 
a position to think twice about taking that drug”. This is sending a mixed 
message on how to approach side effect information. On one hand, it seems 
that a lot of detail is desired, on the other, it could scare the subject into 
avoiding the drug. Yet, the concern may be warranted and may even be a 
motivating factor in making an informed choice. In addition, other aspects of the 
data are open to speculation on how to convey side effects to patients. For a 
statement that asked participants – If pharmacists should put more emphasis 
on the benefits of medications rather than the side effects – 14 agreed, 14 
disagreed, and two were uncertain. A few explained why they disagreed with it. 
How the statement was phrased was a concern for some. Many did not want to 
see benefits stated to the detriment of the risks. Equal emphasis on benefit-risk 
was suggested by some. Others felt it was a physician’s obligation to explain 
any benefits, but the pharmacists’ to cover the side effects. This latter 
suggestion appears to be what occurs during the current practise of 
pharmacists, as mentioned by Dyck et al.7 In that report, pharmacists spent less 
time discussing the overall benefits of medications, instead focusing on side 
effects and safety issues. 
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 Research in the field of risk communication finds that patient education 
about potential adverse effects may be more likely to improve compliance than 
result in the refusal to take the drug.5,11,16,25-27,32,34,88 Pharmacists generally 
counsel individuals about side effects using vague verbal explanation and 
spend less time discussing the benefits of medication.7 Physicians, on the other 
hand, rarely comment on side effects.88 When initiating treatment, it has been 
shown that only one-quarter of physicians discuss potential side effects with 
patients.108 Many appear to be concerned that the power of suggestion might 
lead some patients to experience an increase in side effects if they are fully 
informed about them. 
A few studies have shown that when professionals talk about adverse 
effects of medications using verbal descriptors (i.e. common, rare, may occur), 
most people overestimate their risk.11,12,17,22-27,35, 85,86,103 Berry et al. compared 
the effect of verbal and numerical descriptors of the medication side effects on 
the public’s risk interpertation.103 The verbal descriptors were selected from 
those recommended for use by the European Union (very common, common, 
uncommon, rare, very rare). Five hundred members of the general population 
were presented with a fictitious scenario about visiting the doctor and being 
prescribed medication participated. Information about the medicine’s side 
effects (with probability of getting them) was provided. They found that in all age 
groups tested, participants given a verbal descriptor estimated side effect risk to 
be considerably higher than those given a comparable numerical description. 
The differences in interpretation were reflected in their judgments of side effect 
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 severity, risk to health, and intention to comply. They also confirmed these 
findings using two different verbal descriptors (common and rare) and in 
scenarios which described either relatively severe or relatively mild side effects. 
Only seven out of 180 participants gave a probability estimate which fell within 
the EU assigned numerical range. Researchers concluded large scale use of 
the descriptors could have serious negative consequences for individuals and 
public health. 
An essential component to assist patients in decision-making is the 
presentation of tailored, numeric outcome information associated with various 
medical options. Providing the numerical data (in percentage or frequency) for 
side effects has been suggested by a few studies so that the public could be 
informed about the possible adverse effects and have a better understanding of 
their risk when using it.11,16,17,21,22,25-26,86,103  A frequency format presents the 
chance of occurrence as a proportion of discrete cases over those at risk for an 
occurrence, whereas a probability format typically presents the chance of 
occurrence as a percentage. Several studies have reported advantages in 
using frequencies (e.g. 9 in 100) rather than percentages (e.g. 9 percent),21,90-93 
but Berry et al. have found no difference between people’s interpretations of the 
descriptors using the two different response formats.26 
Another study by Schapira et al. noted the advantages of each format –
frequency formats provide ease of interpretation and simplicity, while probability 
or percentage formats provide an association with personal risk estimation and 
a mathematical quality.109 Probability judgment problems are thought to be 
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 solved by people using a combination of quantitative reasoning and intuitive 
estimation. It has been noted that subjects can easily visualize 10 or 100 
persons and have an intuitive understanding of the magnitude of risk conveyed 
with a frequency format using both denominators.109 Another study by Evans et 
al. found frequency formats were not generally associated with better 
performance than probability formats.110 However, the optimal format to assist 
human judgments is not clear yet.  
For these Saskatoon residents, the study design encompassed both 
frequency and percentage formats concurrently in providing the numerical data. 
Since a clear picture was not evident a priori for the best approach, the decision 
to use both formats was made. There was also a concern that just one format 
may not sufficiently present the information required. It is therefore impossible 
to know which aspect of the two was more pertinent on an individual patient 
basis. Future researchers will need to continue to compare each format 
separately, hopefully on a variety of patients, with different numeracy skill 
levels. 
Adding the numerical data meant subjects had to process more 
information. Regarding the usefulness of increasing the amount of information a 
person may be accustomed to, Schommer et al. suggest there is a balance 
between the need for information at a level sufficient for individuals to make 
decisions and the need not to overload individuals as they cognitively process 
it.80 In the current study, even presenting the two aspects of benefit and harm in 
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 numerical format was found by some to be a lot to process and read. The 
following thought from an interview reflects this issue: 
I had originally said that I thought the percentages would be better option 
[in Form 8]. What I saw … when I read it … it somehow made the 
information more and made me less likely to read it, because it was 
more. [Interview 9] 
 
This point to an obvious notion that adding information could be a burden for a 
group of people who are not interested in receiving it.   
There is debate on whether to present numerical data in a positively- or 
negatively-slanted format. Little empirically derived guidance exists with regard 
to what format to use in presenting numeric risk information.111,112 What is 
known is that bias can occur when risk is presented with a positive versus 
negative frame 68 or with gain versus loss.113,114 A second key aspect under 
study for the Saskatoon group was whether a negative- or positive-slant to side 
effect information impacts on potential medicine use. Participants were asked to 
show their likelihood of taking two medications for headache on a scale of 1 
(very unlikely) to 100 (very likely). Both medications carried one side effect 
(heartburn). The information provided for Drug P (which stood for positively-
slanted wording) stated that 90 out of 100 will not experience heartburn, while 
Drug N (negatively-slanted wording) stated 10 out of 100 will experience 
heartburn. Participants showed a higher mean likelihood of taking a medicine 
(Drug P) when side effects were framed positively. It must be noted that the 
provision of positively- and negatively-slanted information, provided back to 
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 back, allowed patients to consider both angles simultaneously. In real-world 
setting, patients would not be given both. When asked to select an overall 
preferred agent, nine people considered Drug P, while no one chose Drug N. 
Eighteen people preferred Drug N and P equally. The latter group reflected the 
correct interpretation of the information – in spite of the negatively- or positively-
slanted format, the potential to get the side effect was equivalent. However, 
those 18 participants – regardless of correctly preferring the two agents equally 
– did not choose relatively similar locations on the likelihood scales. Even with 
this group, then, the results suggest that not all participants had an intuitive 
understanding of the magnitude of risk conveyed, even comparing two formats 
back to back. Of the people who preferred Drug P, either via differentiation on 
the scale or through outright drug selection, some of the thinking for their 
decision was as follows: 
 
I think N would give you more of a risk of having heartburn than P. 
[Interview 4] 
 
Well I suffer from heartburn, so I thought if this one [Drug P]. It says … 
will not experience heartburn and this one [Drug N] … will experience 
heartburn. So that’s why I went with this one [Drug P] instead of that one, 
because I hate heartburn. [Interview 2] 
 
Only one subject showed higher likelihood of taking Drug N compared to 
Drug P. This is how he explained his thinking: 
Oh, because when given side effects, I preferred the way it was 
expressed – with 10% people would be likely to experience this side 
effect rather than the reverse. I think which could be a little misleading for 
some people, for some patients, that 90 out of 100 will not experience 
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 this. See the not bothers me – I can see them easily being confused, 
thinking that 90 out of 100 will. [Interview 22] 
 
There is some cause for concern here. About half of the subjects 
incorrectly felt Drug P was less likely to cause heartburn. Numeracy skill (or 
lack thereof) is likely an influence here. Information in Table 4.9 draws attention 
to this within our sample, where only 13 of 30 were correct in their interpretation 
of the situation provided within a numeracy test. For others, it appeared that 
when reading the material along a straight line of text, when coming to the word 
“will” (as in, will cause heartburn), this seemed to draw most of their attention 
and in so doing, perhaps led to ignoring any numbers that followed. Finally, the 
power implied by the words will and will not could be factors, as suggested in 
the following interview:  
 
Yeah, I started out with – 90% will not experience heartburn. I think it’s a 
psychological difference – I’m assuming I would be among the 90, I 
think, that would not experience heartburn, so I feel comfortable with 
that. Drug N, on the other hand, says 10 out of 100 will experience 
heartburn which seems like a very positive ... like it’s very … if the word 
was might experience heartburn, I would feel more comfortable with that 
drug. But it says 10 out of 100 will experience heartburn, so that moves it 
down in my preference list. See this one, on the flip side, will not 
experience … it doesn’t say that the other ten, they may be in that group 
as well. Now, if it went on to say – will not experience heartburn, 
however 10 will, then I would put them on an equal playing. [Interview 
10] 
 
Regarding a positively- or negatively-slanted format, other issues arose 
during the interviews. A group of participants did realize the risk of getting 
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 heartburn would be equal in both drugs, but felt the manner of phrasing might 
be potentially confusing to some:  
 
I preferred that one than against Drug P because from all the experience 
I ever had, very seldom do I ever remember a doctor telling me that 90% 
of the people will not get these symptoms or side effects from this drug. 
Generally it’s not very many or 10%, let’s say. It’s not something I think 
you hear. I think you’re more often to get the 10% thrown at you rather 
the 90 who will not. [Interview 11]  
 
I thought that the way information is usually presented is in the possibility 
of getting it. So I just felt that there was a chance to misread the second 
one and think that 90% will. So I thought that just to stay consistent, that 
I actually would prefer this one. So even though I like this better, I liked P 
better. I felt that just kind of my sense of consistency in the way 
information is delivered was important to me, so if some people tell me 
will and some people tell me will not, that just kind of, and maybe 
because I read quickly … not necessarily every word on the piece of 
medication. So I think I just want consistency in how information is 
delivered. So even though I prefer this better, you know how we all like to 
phrase things positively, right? But I did feel that this one [90 will not get] 
is most likely to be misunderstood. [Interview 9] 
 
 Interestingly, participants of this study, of whom more than two-thirds 
held a diploma or degree, were influenced by the positive versus negative 
framing of side effects. Numeracy skills were not the only factor to determine 
participant mindset when deciding which drug they would like better. The 
preference for the kind of format, the interpretation of each format, and 
inattention to key words, were some of the factors cited by participants to 
explain or justify their decision. The findings support the preference reversals 
theory, that people switch preferences for one outcome over another based 
solely on how outcomes are presented, even though their losses and gains are 
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 the same. It is still unknown how and why given elements of risk format 
influence patient risk perceptions and reasoning. 
 Looking at other literature on the framing effect, one review of 40 studies 
examined the effect of framing on treatment, immunization, or health behaviour 
scenarios.60 Active treatments like surgery was preferred to other treatments 
when treatment efficacy was presented in a positive frame (survival) rather than 
a negative frame (mortality). Framing affects were less obvious for 
immunization and health behaviour scenarios. However, those with little interest 
in the behaviour at baseline were influenced by framing, particularly when 
information was presented as gains. Framing effects varied with the type of 
scenario, responder characteristics, scenario manipulations, and study quality. 
This is in line with Study 2 findings and results of the numeracy test (see Table 
4.9). Using an OTC drug for a headache is of far less importance compared to 
undergoing surgery, but the results showed participant responses were affected 
by positive or negative framing.  
 Moxey concluded that when describing treatment effects to patients, 
expressing the information in more than one way may present a balanced view 
to patients and enable them to make informed decisions.60 When designing side 
effect sections of medication leaflets, positive framing could be used in styles 
that draw patient attention to the numerical data. Presenting numerical data 
positively may also need the right emphases on numbers and words (e.g. 99 
out of 100 did not) to make sure patients see the key content.  
 
 
 
113
 5.1. Limitations 
 Volunteering for the study may potentially bias the sample. Volunteers 
can have certain characteristics that differentiate them from the population of 
patients as a whole.  
The high literacy level of our participants – a third had an education level 
higher than a bachelor's degree – may be another limitation in generalizing our 
sample to the population of people 50 years and older. However, a comparison 
of the data from the 2006 Saskatoon Census for adults (35-64 years) showed 
that the education level of the study sample was only seven percent higher than 
the general population.107 There was no data specific to the 50-plus population. 
 The SF-8 health survey was undertaken to determine whether the 
subjects were sicker or healthier than the average person of similar ages in 
society. However, there was no data available for overall health status of 
Saskatoon adults for comparison. In other reports, most SF-8 data allowed for 
comparing data before and after a suggested treatment in order to control for 
quality of life.99,115 The overall mean score for all 30 participants was 32.4 ± 5.7, 
with a score that could range from eight to 42 (42 would represent major 
physical and mental concern). This result shows that there were some concerns 
for participant health. This issue was seen during the interview as well. For a 
group of participants who were using many medications already, adding 
another OTC drug raised anxiety and probably affected their decision to use a 
medicine for headaches.  
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  Use of scales to quantify the behaviour of participants is another 
limitation of the study.  
 The choice of side effects (diarrhoea, dry eyes, etc) did have an effect on 
participant likelihood to take a medicine. There may have been different results 
for this study if the chosen side effects were milder or more severe. While the 
percentages chosen were reflective of rates seen for actual agents, different 
reactions by participants could have occurred if frequencies were higher than 
10 percent, for example (a level that could be defined as very common).  
 Including both the percentages and frequency data was a limitation in 
some respects, in that it did not allow for an assessment of which of the two 
formats was most influential to any person. For some, the two could have been 
helpful. For others, it could have been perceived as an extra bit of material to 
process. Future research may be able to assess the effect of each separately 
on people’s decision to use a medicine. 
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 CHAPTER 6 
CONCLUSION AND RECOMMENDATIONS 
People are being encouraged to monitor their own illnesses, undertake 
lifestyle changes to prevent diseases and maintain their health. They are also 
being encouraged to self-treat minor illnesses such as colds, headaches, and 
heartburn. Most patients want to be involved in decisions relating to their health. 
Decisions such as whether to undertake a course of treatment, and which 
treatment to choose, can only be truly shared if the patient has a similar 
understanding of the possible advantages and disadvantages of each option as 
the clinician. Accurate and effective risk communication is therefore of great 
importance in establishing trust, reaching shared agreements and developing 
concordant clinical management plans. 
Regarding fictitious OTC agents and hypothetical illness scenarios, 
participant preference revealed medication information leaflets may benefit by 
including frequency data for side effects. It appeared that seeing the frequency 
data did lessen fears or concerns for that chosen agent. Adding it to written 
information leaflets or to verbal content could decrease fears and improve 
patient intention to take their medicine. But in spite of this evidence, one should 
be wary about concluding that such leaflets (or pharmacists) should include 
frequency data with side effect information in practice. More research needs to 
be done on this issue with larger samples, across all adult age groups, and for a 
variety of acute and chronic illnesses.  
 
 
116
 When numerical data for side effects is phrased positively, participants 
showed higher likelihood of taking a medicine. Giving estimations for the side 
effects listed on medication leaflets could be helpful for patients with greater 
informational needs, and framing it in a positive format may impact on use. 
However, this approach may conflict with the tenets of informed choice and 
could reflect a paternalistic view. A minimum condition for the achievement of 
informed choice is for the care giver to inform the patient of all the necessary 
information that is relevant to making the decision, in a clear and concise 
manner. Further research in the clinical setting is needed to provide justification 
for the format used when presenting risk information to patients. Studies also 
should focus on optimizing these interventions, identifying tools that a patient is 
most likely to benefit from, and improving cost-effectiveness. This insight could 
then be the platform for informed discussion about the significance and burden 
of risks and the implications for the individual or family concerned. It may make 
the explanation of diseases and their treatment easier. Instruction in the 
efficient communication of statistical information should be part (or continue to 
be part) of health care curricula and continuing education for health care 
providers. 
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 APPENDIX A 
IN-PHARMACY RECRUITMENT POSTER (11” X 17”) 
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 Talking About the Side Effects of Medicines 
 
 
We could use your help 
 
The Pharmacy program at University of 
Saskatchewan is looking for ways to improve 
how pharmacists tell patients about side effects. 
We have asked this pharmacy to help identify 
people who might want to help us try to do this. 
 
What is required of you? 
 
Not a lot! About one hour of your time. You fill out a 
few forms. We then would like to hear about your 
preferences regarding information styles. 
 
It’s easy; we just need your opinions! 
No qualifications are really needed, other 
than being 50 or older and the ability to read 
and write (and living in Saskatoon). 
 
Your feedback is valuable, but so is your time… 
That’s why we want to provide $30 for your time. 
 
Interested? You can contact: 
 
Mahsa Hosseini, B.Ed 
966-6346 
College of Pharmacy and Nutrition 
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 APPENDIX B 
LETTER TO PHARMACISTS REQUESTING THEIR ASSISTANCE IN 
PATIENT ACCRUAL 
 
[Pharmacist Name]                                                                September, 2007 
[Pharmacy Name & address] 
Saskatoon, SK [postal code] 
 
RE: Recruiting patient volunteers from your pharmacy for a study on side 
effect information 
Dear [          ]: 
The EduLab Program at the College of Pharmacy and Nutrition was created to 
examine how pharmacists interact with patients concerning health-related 
matters (focusing on drug therapy). Since, it has been involved with: 
 
3 the Pharmacist Intervention in Risk Reduction (PIRR) study, where 
almost 200 high-risk cardiac patients have been helped by community 
pharmacists; 
 
3 a project in one Saskatoon pharmacy to determine whether ‘coaching’ 
can entice the public to ask more questions about drug therapy; 
 
3 a study with local volunteer pharmacists to examine the order in which 
community pharmacists present information to patients; 
 
3 a study with local volunteer pharmacists to examine whether visuals 
during patient counselling leads to more satisfaction when compared to 
our typical drug information leaflets. 
 
For our next project, we would like to know more about patient preferences for 
presenting side effect information numerically (e.g. “There is a 1% chance of 
getting a rash with this drug …”) versus using a verbal descriptor (e.g. “There is 
a small chance of getting a rash with this drug…”). We also plan to look into 
preferences for a positive format (e.g. “Most won’t get this side effect …”) 
versus a negative format (e.g. “A few will get this side effect …”) on how 
information might be conveyed. 
 
Why have we contacted you?  
We could use some help in finding volunteers for this project. We are looking for 
people aged 50 years and over who are reasonably fluent in English. For this, 
30 pharmacies have been contacted in the hopes of finding 40 volunteers. You 
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 would be asked to consider placing an 8 1/2 inch by 11 inch laminated sign (for 
two weeks) near your dispensary to advertise the project. We also have 
prescription bag stuffers for those you feel might be interested.  
 
If you can help out, thank you. Or, if you want more information, please contact 
Dr. Jeff Taylor at 966-5328 or Mahsa Seyed-Hosseini at 477-2792. 
 
Sincerely, 
_______________________                ________________________________ 
Jeff Taylor, EduLab Director                 Mahsa Seyed-Hosseini, Graduate 
student 
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 APPENDIX C 
CONSENT FORM 
 
Presenting Side Effect Information and the Influence on Patient Medicine-
Taking Behaviour 
 
Thank you for considering to be a participant in this study. The purpose is to 
explore different ways to discuss medicine side effects with the people who take 
them.  
 
In order to protect the interests of the participants, what will be required of you 
is as follows: 
 
1. You will be asked some personal questions, respond to several situations 
involving the use of medicines and the side effects they may cause, then 
participate in an interview about your choices. The personal information and the 
situations involving medicines are contained in a booklet. It will take about 35 
minutes to complete this section. For questions about medicines and side 
effects, there are no right or wrong answers; we just want your opinions. The 
researcher during one single interview will discuss your thoughts about side 
effect presentations. This conversation will be tape-recorded and you can 
request to have the recorder turned off at any time. The reasons for your 
opinions, and the barriers to understanding this information, will be considered 
important to us.   
 
2. The background information, the scenarios, and interview will last for about 1 
to 1 ½ hour. You can withdraw at any time during the study for any reason and 
without consequence. If you withdraw, the data collected from your participation 
will not be published in our study results. 
 
3. The interview will be tape-recorded, then transcribed and analyzed to 
uncover any themes in what was discussed. You will be given a version of the 
transcripts in which false starts, repetitions, and utterances (um, eh etc) have 
been removed to make it more readable. You can add, delete or change 
information to reflect what you want to say. You will be asked to sign a Letter of 
Consent for Release of Transcripts following your satisfactory review of the 
transcript. You will be able to receive a summary copy of the study following its 
completion.  
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 4. The data collected from you will be kept in a secure place and will be held at 
the University of Saskatchewan with the researcher’s supervisor, Dr. Jeff 
Taylor, for five years according to the University of Saskatchewan guidelines.  
 
5. The results of the study will be used for a master’s thesis. The confidentiality 
and anonymity of the participants will be protected through the use of 
pseudonyms. 
 
6. Participants of this study will receive a stipend of $30 as our thanks for 
spending part of your day with us. The benefits to us as researchers will be 
greater understanding of how patients prefer to learn about medication side 
effects.  
 
7. Your participation in this study is completely voluntary. You have the right to 
refuse to participate in the study and/or withdraw from study at any time, for any 
reason. You will receive $30 if you even decide to leave before the study is 
finished.  
 
If you have any questions about your participation or your rights as a participant 
in this study, you may contact the Ethics Office at the University of 
Saskatchewan (966-2084) or you can contact me, Mahsa Seyed-Hosseini, at 
966-6346, or my supervisor, Dr. Jeff Taylor, College of Pharmacy and Nutrition, 
966-5328.  
 
 
I,                                                    , understand that this research project has 
been approved by the University of Saskatchewan Behavioural Research Ethics 
Board on August 28, 2007 and I agree to participate. I am aware of the nature 
of the study and understand what is expected of me and I also understand that I 
am free to withdraw at any time throughout the study. A copy of this form has 
been given to me for my records and at the end of the study I will receive a 
copy of the report. 
 
Participant signature _________________________ Date ______________ 
 
___________________________ 
Mahsa- Seyed-Hosseini 
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 APPENDIX D 
LETTER OF CONSENT FOR RELEASE OF TRANSCRIPTS 
 
I appreciate your participation in the research study: Presenting Side Effect 
Information and the Influence on Patient Medicine-Taking Behaviour.  
 
Since the interview was tape-recorded, we are obliged to let you see the 
transcript. This requires sending you a copy of our conversation by mail. What 
will be required of you would be as follows: 
 
Please read and re-check the transcripts for accuracy of information. You 
may add or clarify the transcripts to say what you intended to mean or 
include additional comments that will be your words. You may also 
delete any information that you may not want to be quoted in the study. 
 
However, if you DON’T feel the need for a copy of the transcript of your taped 
interview, please check this box  
 
The interpretation of this study will be used in a master’s thesis. Except for the 
researchers in the study, your participation has remained confidential. The 
result of this study will be used to write an article for a pharmaceutical journal. 
Individual patient names will NOT be used; only anonymous pooled data is 
used for this purpose. 
 
In accordance with the University of Saskatchewan Behavioural Research 
Ethics Board, the tape recordings, writing samples, and transcriptions made 
during the study will be kept with the supervisor in a locked file until the study is 
finished. After completion of the study, the tapes and other data will be kept for 
five years at the University of Saskatchewan and then destroyed. 
 
Please check this box if you would like a copy of the study summary when 
available: 
 
 
              to be sent to:     _____________________ 
 
  _____________________ 
 
    _____________________ 
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 I,                                                                 understand the guidelines above and 
agree to release the revised transcripts to the researcher. A copy of the 
transcript release form is provided for your records. 
 
Participant’s Signature______________________ Date_________________  
 
Researcher's Signature _____________________ 
                                      Mahsa Seyed-Hosseini 
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 APPENDIX E 
FORM 1 
ID#: ________________                        Date: _______________ 
 
Please check 9one box of the following answers which best describes your 
situation. 
1. What is your gender?       Male             Female 
 
2. What year were you born? (Please write the year in the blank area)  
19___ 
 
3. What is the highest level of education that you completed? 
 Less than grade 12 
 High school diploma or equivalent 
 Some university or technical school education 
 Technical school diploma or a university Bachelor’s degree 
 Other ___________________ 
 
4. Are you currently taking any prescribed medications?     
 Yes          No 
 
5. Are you currently taking any medications available without a prescription, 
also called over-the-counter medicines (e.g. pain killers, heartburn products, 
herbal remedies)?      Yes          No 
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6. Given any past history with prescription medicine use, how would you 
describe your knowledge of prescription medicines? 
 
 Very knowledgeable 
 Knowledgeable 
 Somewhat Knowledgeable 
 Not very Knowledgeable 
 Does not apply to me; I have rarely used prescribed medicines 
 
 
7. Given any past history with over-the-counter (OTC) medicine use, how 
would you describe your knowledge of OTC medicines? 
 
 Very knowledgeable 
 Knowledgeable 
 Somewhat Knowledgeable 
 Not very Knowledgeable 
 Does not apply to me; I have rarely used OTC medicines 
 
8. Have you had any experience with a side effect (caused by a medicine) in 
the last 6 months? 
 Yes          No          Unsure 
If you answered yes, please indicate with a “9” which of the following side 
effects you have experienced? 
 Nausea                Rash               Dizziness 
 Heartburn            Diarrhoea        Dry eyes 
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Please indicate the extent to which you agree or disagree with the 
following statements by ticking the appropriate box. 
 
9. I like to receive information about my medications’ side effects. 
                                                                                                
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
10. I read medication leaflets or written information provided by   pharmacists. 
                                                                                                
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
11. Side effect information provided to me puts me in a position to think twice 
about taking that drug.   
                                                                                                
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
12. Pharmacists should give detailed information to all individuals regarding 
mild and frequent side effects. 
                                                                                                
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
13. Pharmacists should give detailed information to all individuals regarding 
mild and rare side effects. 
                                                                                                
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
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 14. Pharmacists should give as much information concerning side effects as 
he or she thinks best for the individual patient.  
                                                                                                
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
15. Pharmacists should put more emphasis on the benefits of medications 
rather than the side effects. 
                                                                                                
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
16. Side effects can be communicated to patients by listing them, with the 
option of adding numbers that represent the percentage of people who 
experience a particular side effect.  
For example, a pharmacist or doctor could say:  
1) “The most common side effects are stomach ache, back 
ache, and drowsiness.” 
Or they could say:  
2) “The most common side effects are stomach ache 
(12%), back ache (6%), and drowsiness (2%).”  
Which approach, if any, do you prefer? 
      Option 1 (just the side effects)    
  Option 2 (the side effects and the percentages) 
  No preference 
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 APPENDIX F 
FORM 2 
 
Belief about Medication Questionnaire (BMQ - General) © 
We would like to ask you about your personal views about medicines in 
general.  
These are statements other people have made about medicines in general.  
Please indicate the extent to which you agree or disagree with them by 
ticking the appropriate box.  
There are no right or wrong answers. We are interested in your personal 
views.  
 
a) Doctors use too many medicines 
                                                                                                          
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
b) People who take medicines should stop their treatment for a while every now 
and again  
                                                                                                          
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
c) Most medicines are addictive  
                                                                                                          
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
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 d) Natural remedies are safer than medicines 
                                                                                                          
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
e) Medicines do more harm than good  
                                                                                                          
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
f) All medicines are poisons 
                                                                                                          
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
g) Doctors place too much trust on medicines 
                                                                                                          
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
 
h) If doctors had more time with patients they would prescribe fewer medicines. 
                                                                                                          
Strongly agree      Agree      Uncertain      Disagree      Strongly disagree  
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 APPENDIX G 
FORM 3 (SF-8) 
 
 This survey asks for your views about your health. 
 For each of the following questions, please mark an [3] in the one box that 
best describes your answer. 
 If you are unsure about how to answer a question, please give the best 
answer you can. 
 
 
 
1) Overall, how would you rate your health during the past 4 weeks? 
 
                                                                                
Excellent       Very good       Good       Fair       Poor       Very poor 
 
 
2) During the past 4 weeks, how much did physical health problems limit 
your usual physical activities (such as walking or climbing stairs)? 
 
                                                                                              
Not at all      Very little      Somewhat      Quite a lot      Could not do  
                                                                                      physical activities 
 
 
3) During the past 4 weeks, how much difficulty did you have doing your daily 
work, both at home and away from home, because of your physical health? 
 
                                                                                           
None at all      A little bit      Some      Quite a lot        Could not do  
                                                                                      daily work 
 
 
4) How much bodily pain have you had during the past 4 weeks? 
 
                                                                                    
None       Very Mild       Mild       Moderate       Severe       Very Severe 
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5) During the past 4 weeks, how much energy did you have? 
 
                                                                                       
Very much          Quite a lot          Some          A little          None 
 
 
6) During the past 4 weeks, how much did your physical health or emotional 
problems limit your usual social activities with family or friends? 
 
                                                                                             
Not at all      Very little      Somewhat      Quite a lot      Could not do  
                                                                                        social activities 
 
 
7) During the past 4 weeks, how much have you been bothered by emotional 
problems (such as feeling anxious, depressed or irritable)? 
 
                                                                                                 
Not at all        Slightly        Moderately        Quite a lot        Extremely 
 
 
8) During the past 4 weeks, how much did personal or emotional problems 
keep you from doing your usual work, school or other daily activities? 
 
                                                                                            
Not at all      Very little      Somewhat      Quite a lot      Could not do  
                                                                                        daily activities 
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 APPENDIX H 
FORM 5 (REALM) 
Rapid Estimate of Adult Literacy in Medicines (REALM) 
 
Directions for the person giving the test to a subject 
1. Give the patient a laminated copy of the REALM form and score answers on 
an un-laminated copy that is attached to a clipboard. Hold the clipboard at an 
angle so that the patient is not distracted by your scoring. Say: 
“We understand that sometimes health instructions are given with very complicated 
words or phrases. To get an idea of how familiar you might already be with medical 
terms, we are going to ask you some questions about a series of words. Don’t 
worry if you don’ understand or have never heard of some of them, this is 
common.” 
  
"I want to hear you read as many words as you can from this list. Begin with the 
first word in List 1 and read aloud. When you come to a word you cannot read, do 
the best you can or say, 'blank' and go onto the next word." 
2. If the patient takes more than five seconds on a word, say "blank" and point 
to the next word, if necessary, to move the patient along. If the patient begins to 
miss every word, have him or her pronounce only known words. 
3. Count as an error any word not attempted or mispronounced. Score by 
marking a plus (+) after each correct word, a check (4) after each 
mispronounced word, and a minus (-) after words not attempted. Count as 
correct any self-corrected words. 
4. Count the number of correct words for each list, and record the numbers on 
the "Score" line. Total the numbers, and match the score with its grade 
equivalent in the table below. 
TABLE Scores and Grade Equivalents for the REALM Questionnaire 
Raw score Grade range 
0 to 18 Third grade and below; will not be able to read most low-literacy materials; 
will need repeated oral instructions, materials composed primarily of 
illustrations, or audio or video tapes 
19 to 44 Fourth to sixth grade; will need low-literacy materials, may not be able to 
read prescription labels 
45 to 60 Seventh to eighth grade; will struggle with most patient education materials; 
will not be offended by low-literacy materials. 
61 to 66 High school; will be able to read most patient education materials. 
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List 1  List 2  List 3  
Fat  Fatigue  Allergic  
Flu  Pelvic  Menstrual  
Pill  Jaundice  Testicle  
Dose  Infection  Colitis  
Eye  Exercise  Emergency  
Stress  Behaviour  Medication  
Smear  Prescription  Occupation  
Nerves  Notify  Sexuality  
Germs  Gallbladder  Alcoholism  
Meals  Calories  Irritation  
Disease  Depression  Constipation  
Cancer  Miscarriage  Gonorrhoea  
Caffeine  Pregnancy  Inflammatory  
Attack  Arthritis  Diabetes  
Kidney  Nutrition  Hepatitis  
Hormones  Menopause  Antibiotics  
Herpes  Appendix  Diagnosis  
Seizure  Abnormal  Potassium  
Bowel  Syphilis  Anaemia  
Asthma  Haemorrhoids  Obesity  
Rectal  Nausea  Osteoporosis  
Incest  Directed  Impetigo  
      
List 1 score _____ List 2 score ______ List 3 score ____ 
    
 
Raw score _____ 
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 APPENDIX I 
FORM 6 (NUMERACY TEST) 
1. Imagine that we flip a coin 1000 times. What is your best guess about how 
many times the coin would come up heads in 1000 flips? ____ times out of 
1000 
 
2. In the Big Bucks Lottery, the chance of winning a $10 prize is 1%. What is 
your best guess about how many people would win a $10 prize if 1000 people 
each buy a single ticket to Big Bucks? _______ person(s) out of 1000 
 
3. In the ACME Publishing Sweepstakes, the chance of winning a car is 1 in 
1000. What percent of tickets to ACME Publishing Sweepstakes win a car? 
 ________ percent (%) 
 
4. Mr. Roe needs surgery.  9 in 1000 people die from this surgery. How would 
you describe the surgery? 
 
 Very risky 
 Risky 
 Slightly risky 
 Not risky  
 
5. Mrs. Smith is told she has a 1 in 296 chance of dying from cancer and a 1 in 
407 chance of dying from a stroke. Which is bigger, Mrs. Smith’s chance of 
dying from a stroke or cancer?  
 
 Stroke 
 Cancer 
 Chances are the same 
 
6. Mr. Smythe needs surgery.  991 in 1000 people survive this surgery.   
How would you describe the surgery? 
 
 Very risky 
 Risky 
 Slightly risky 
 Not risky 
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 APPENDIX J 
DESIGN OF STUDY 1 
First ½ of Subjects (N=15) 
 
Mild Headache Scenario without Side Effect Frequency 
 
 
 
  Drug X                           Drug Y                        Drug Z  
  
   50%                               75%                             100%  
effective                         effective                      effective  
 
Nausea                          Nausea                         Nausea  
Rash                              Rash                             Rash            
                                      Dizziness                      Dizziness      
                                      Heartburn                     Heartburn           
                                                                           Diarrhea       
                                                                           Dry eyes         
|--------------------------------------------------------------------------------------------------------| 
                      Likelihood of taking each agent 
                                    Preferred drug 
 
Mild Headache Scenario with Side Effect Frequency 
 
 
         Drug X                           Drug Y                                Drug Z 
 
           50%                               75%                                    100% 
       effective                       effective                              effective 
 
Nausea 3% (3 in 100)   Nausea 3% (3 in 100)            Nausea 3% (3 in 100) 
Rash 4% (4 in 100)       Rash 4% (4 in 100)               Rash 4% (4 in 100) 
                                      Dizziness 7% (7 in 100)        Dizziness 7% (7 in 100) 
                                      Heartburn 5% (5 in 100)       Heartburn 5% (5 in 100) 
                                                                                    Diarrhoea 2% (2 in 100) 
                                                                                    Dry eyes <1% (< 1 in 100) 
|--------------------------------------------------------------------------------------------------------| 
Likelihood of taking each agent 
Preferred drug 
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Form 6 (Booklet 1) 
 
Participant Instructions for Study 1  
Mild Headache Scenario  
 
Whether true or not, consider for a moment that you get headaches. They tend 
to be mild and occur 6 times a year. You need a pain killer for these 
headaches in order to focus better on your daily activities. You have the choice 
of the following 3 headache medicines for relief: 
 
 
Drug X  
This drug is 50% effective (reduces pain by half within 10 minutes) for 
mild to moderate headaches. This drug may cause nausea and rash. 
 
 
Drug Y  
This drug is 75% effective (reduces pain by 75% within 10 minutes) for 
mild to moderate headaches. This drug may cause nausea, rash, 
dizziness and heartburn. 
 
 
Drug Z  
This drug is 100% effective (reduces all the pain within 10 minutes) for 
mild to moderate headaches. This drug may cause nausea, rash, 
dizziness, heartburn, diarrhoea and dry eyes.  
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 Form 6 (Booklet 1) 
 
Participant Instructions for Study 1 
Mild Headache Scenario  
 
Given what you just read about the 3 agents for headaches, how likely is it that 
you would take each drug? For this, please draw a line across any point on the 
scale that reflects your opinion.  
 
For example:  
|..................|...............................................................................| 
 
 
1. How likely is it that you would take Drug X? 
 
 |..................................................................................................| 
Very                                                                                                                Very  
Unlikely                                                                                                         Likely 
 
 
2. How likely is it that you would take Drug Y? 
 
 |..................................................................................................| 
Very                                                                                                               Very  
Unlikely                                                                                                         Likely 
 
 
3. How likely is it that you would take Drug Z? 
 
 |..................................................................................................| 
Very                                                                                                               Very  
Unlikely                                                                                                         Likely 
 
 
 
4. If you were in a position where you have to decide to use a painkiller, which 
one you would take? 
 
 Drug X            Drug Y             Drug Z           None 
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Form 7 (Booklet 1) 
 
Participant Instructions for Study 1  
Mild Headache Scenario  
 
 
Again consider that you get headaches. And as before, they tend to be mild 
and occur 6 times a year. You need a pain killer for these headaches in order 
to focus better on your daily activities. You have the choice of the following 3 
headache medicines for relief:  
 
 
Drug X  
This drug is 50% effective (reduces pain by half within 10 minutes) for 
mild to moderate headaches. This drug may cause nausea 3% (in 3 of 
100 users) and rash 4% (in 4 of 100 users). 
 
 
Drug Y 
This drug is 75% effective (reduces pain by 75% within 10 minutes) for 
mild to moderate headaches. This medicine may cause nausea 3% (in 3 
of 100 users), rash 4% (in 4 of 100 users), dizziness 7% (in 7 of 100 
users), and heartburn 5% (in 5 of 100 users). 
 
 
Drug Z  
This drug is 100% effective (reduces all the pain within 10 minutes) for 
mild to moderate headaches. This medicine may cause nausea 3% (in 3 
of 100 users), rash 4% (in 4 of 100 users), dizziness 7% (in 7 of 100 
users), heartburn 5% (in 5 of 100 users), diarrhoea 2% (in 2 of 100 
users), and dry eyes <1% (in less than 1 of 100 users). 
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 Form 7(Booklet 1) 
 
Participant Instructions for Study 1  
Mild Headache Scenario  
  
Given what you just read about the 3 agents for headaches, how likely is it that 
you would take each drug? For this, please draw a line across any point on the 
scale that reflects your opinion.  
 
For example:  
|..................|...............................................................................| 
 
 
5. How likely is it that you would take Drug X? 
 
 |..................................................................................................| 
Very                                                                                                               Very  
Unlikely                                                                                                        Likely 
 
 
6. How likely is it that you would take Drug Y? 
 
 |..................................................................................................| 
Very                                                                                                               Very  
Unlikely                                                                                                        Likely 
 
 
7. How likely is it that you would take Drug Z? 
 
 |..................................................................................................| 
Very                                                                                                              Very  
Unlikely                                                                                                        Likely 
 
 
 
 8. If you were in a position where you have to decide to use a painkiller, which 
one YOU would take? 
 
 Drug X            Drug Y             Drug Z            None 
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 Form 8 (Booklet 1) 
 
 
Preference question for Mild Headache Scenario 
 
 
9. From what you read, which explanation would YOU prefer to be 
given on medication side effects? Check ONE of the following options: 
 
 The first version (a list of possible side effects) 
 
 The second version (a list of possible side effects plus the 
     percentages that they may occur) 
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 Design of Study 1 
 
Second ½ of Subjects (n=15) 
 
Severe Headache Scenario without Side Effect Frequency 
 
 
 
  Drug X                           Drug Y                        Drug Z  
  
   50%                               75%                             100%  
effective                         effective                      effective  
 
Nausea                          Nausea                         Nausea  
Rash                              Rash                             Rash  
                                      Dizziness                      Dizziness     
                                      Heartburn                     Heartburn   
                                                                           Diarrhoea       
                                                                           Dry eyes         
|--------------------------------------------------------------------------------------------------------| 
                      Likelihood of taking each agent 
                                    Preferred drug 
 
 
Severe Headache Scenario with Side Effect Frequency 
 
 
         Drug X                           Drug Y                                Drug Z 
 
           50%                               75%                                    100% 
       effective                       effective                              effective 
 
Nausea 3% (3 in 100)   Nausea 3% (3 in 100)            Nausea 3% (3 in 100) 
Rash 4% (4 in 100)       Rash 4% (4 in 100)               Rash 4% (4 in 100) 
                                      Dizziness 7% (7 in 100)        Dizziness 7% (7 in 100) 
                                      Heartburn 5% (5 in 100)       Heartburn 5% (5 in 100) 
                                                                                    Diarrhoea 2% (2 in 100) 
                                                                                    Dry eyes <1% (< 1 in 100) 
 
|--------------------------------------------------------------------------------------------------------| 
Likelihood of taking each agent 
Preferred drug 
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Form 6 (Booklet 2) 
 
Participant Instructions for Study 1 
Severe Headache Scenario 
  
Whether true or not, please consider for a moment that you get headaches. 
They tend to be severe and occur twice a year. You need a pain killer in order 
to get out of the bed. You have the choice of the following 3 headache 
medicines for relief: 
 
 
Drug X  
This drug is 50% effective (reduces pain by half within 10 minutes) for 
mild to moderate headaches. This drug may cause nausea and rash. 
 
 
Drug Y  
This drug is 75% effective (reduces pain by 75% within 10 minutes) for 
mild to moderate headaches. This drug may cause nausea, rash, 
dizziness and heartburn. 
 
 
Drug Z  
This drug is 100% effective (reduces all the pain within 10 minutes) for 
mild to moderate headaches. This drug may cause nausea, rash, 
dizziness, heartburn, diarrhoea and dry eyes. 
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 Form 6(Booklet 2) 
 
Participant Instructions for Study 1  
Severe Headache Scenario  
  
Given what you just read about the 3 agents for headaches, how likely is it that 
you would take each drug? For this, please draw a line across any point on the 
scale that reflects your opinion.  
 
For example:  
|..................|...............................................................................| 
 
 
 
1. How likely is it that you would take Drug X? 
 
 |..................................................................................................| 
Very                                                                                                                Very  
Unlikely                                                                                                         Likely 
 
 
2. How likely is it that you would take Drug Y? 
 
 |..................................................................................................| 
Very                                                                                                                Very  
Unlikely                                                                                                         Likely 
  
 
3. How likely is it that you would take Drug Z? 
 
 |..................................................................................................| 
Very                                                                                                                Very  
Unlikely                                                                                                         Likely 
 
 
 
4. If you were in a position where you have to decide to use a painkiller, which 
one you would take? 
 
 Drug X             Drug Y              Drug Z            None 
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 Form 7 (Booklet 2) 
 
Participant Instructions for Study 1  
Severe Headache Scenario  
 
Again consider that you get headaches. And as before, they tend to be severe 
and occur twice a year. You need a pain killer in order to get out of the bed. 
You have the choice of the following 3 headache medicines for relief: 
 
 
Drug X  
This drug is 50% effective (reduces pain by half within 10 minutes) for 
mild to moderate headaches. This drug may cause nausea 3% (in 3 of 
100 users) and rash 4% (in 4 of 100 users). 
 
 
Drug Y 
This drug is 75% effective (reduces pain by 75% within 10 minutes) for 
mild to moderate headaches. This medicine may cause nausea 3% (in 3 
of 100 users), rash 4% (in 4 of 100 users), dizziness 7% (in 7 of 100 
users), and heartburn 5% (in 5 of 100 users). 
 
 
Drug Z  
This drug is 100% effective (reduces all the pain within 10 minutes) for 
mild moderate headaches. This medicine may cause nausea 3% (in 3 of 
100 users), rash 4% (in 4 of 100 users), dizziness 7% (in 7 of 100 users), 
heartburn 5% (in 5 of 100 users), diarrhoea 2% (in 2 of 100 users), and 
dry eyes <1% (in less than 1 of 100 users). 
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 Form 7(Booklet 2) 
 
Participant Instructions for Study 1 
Severe Headache Scenario 
 
  
Given what you just read about the 3 agents for headaches, how likely is it that 
you would take each drug? For this, please draw a line across any point on the 
scale that reflects your opinion.  
 
For example:  
|..................|...............................................................................| 
 
 
 
5. How likely is it that you would take Drug X? 
 
 |..................................................................................................| 
Very                                                                                                                Very  
Unlikely                                                                                                         Likely 
  
 
6. How likely is it that you would take Drug Y? 
 
 |..................................................................................................| 
Very                                                                                                                Very  
Unlikely                                                                                                         Likely 
  
 
7. How likely is it that you would take Drug Z? 
 
 |..................................................................................................| 
Very                                                                                                                Very  
Unlikely                                                                                                         Likely 
  
 
 
8. If you were in a position where you have to decide to use a painkiller, which 
one you would take? 
  
 Drug X              Drug Y              Drug Z            None 
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 Form 8 (Booklet 2) 
 
Preference Question for Severe Headache Scenario 
 
 
9. From what you read, which explanation would YOU prefer to be given on 
medication side effects? Check ONE of the following options: 
 
 The first version (a list of possible side effects) 
 
 The second version (a list of possible side effects plus the  
     percentages that they may occur) 
 
 No preference 
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 APPENDIX K 
DESIGN OF STUDY 2 
 
 
 
All Subjects 
 
 
 
½ Sample                                               ½ Sample 
 
 
Drug N: Negatively-slanted wording Drug P: Positively-slanted wording 
 
Drug P: Positively-slanted wording Drug N: Negatively-slanted wording 
 
|--------------------------------------------------------------------------------------------------------| 
 
 
 
 
Likelihood of taking the medicine 
Participant preference for explanation style 
Participant preference for drug use (effect of framing) 
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  Form 9 (Booklet 1) 
 
Participant Instructions for Study 2  
The following information concerns 2 different medicines used for headaches. 
Please read the two passages and respond to the questions that follow for 
each.  
 
Drug N is an effective drug for headache, but it can cause some side effects. 
One of those side effects is heartburn. Regarding how often this might occur, 
10% (that is, 10 out of 100) of users WILL experience heartburn when taking 
this medicine. 
 
1. Given what you just read, how likely is it that you would take this drug? For 
this, please draw a line across any point on the scale that reflects your opinion.  
 
 |..................................................................................................| 
Very                                                                                                                Very  
Unlikely                                                                                                         Likely 
 
Drug P is an effective drug for headache, but it can cause some side effects. 
One of those side effects is heartburn. Regarding how often this might occur, 
90% (that is, 90 out of 100) of users WILL NOT experience heartburn when 
taking this medicine. 
 
2. Given what you just read, how likely is it that you would take this drug? For 
this, please draw a line across any point on the scale that reflects your opinion. 
 
|..................................................................................................| 
Very                                                                                                                Very 
Unlikely                                                                                                         Likely  
 
3. What drug would you prefer to use if you had a headache in the next few 
days? Check ONE of the following options: 
 
      Drug N 
      Drug P  
      I would prefer the 2 agents equally 
      I would prefer neither agent 
 
4. The passages you just read mentioned a heartburn side effect and how often 
it might occur. From what you read, which explanation would YOU prefer to be 
given on its occurrence? Check ONE of the following options: 
 
 The first version (a focus on who WILL get heartburn) 
 The second version (a focus on who WILL NOT get heartburn) 
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 Form 9 (Booklet 2) 
 
Participant Instructions for Study 2 
The following information concerns 2 different medicines used for headaches. 
Please read the two passages and respond to the questions that follow for 
each.  
 
Drug P is an effective drug for headache, but it can cause some side effects. 
One of those side effects is heartburn. Regarding how often this might occur, 
90% (that is, 90 out of 100) of users WILL NOT experience heartburn when 
taking this medicine. 
 
1. Given what you just read, how likely is it that you would take this drug? For 
this, please draw a line across any point on the scale that reflects your opinion. 
 
 |..................................................................................................| 
Very                                                                                                                Very  
Unlikely                                                                                                         Likely 
 
Drug N is an effective drug for headache, but it can cause some side effects. 
One of those side effects is heartburn. Regarding how often this might occur, 
10% (that is, 10 out of 100) of users WILL experience heartburn when taking 
this medicine. 
 
2. Given what you just read, how likely is it that you would take this drug? For 
this, please draw a line across any point on the scale that reflects your opinion.  
 
 |..................................................................................................| 
Very                                                                                                                Very  
Unlikely                                                                                                         Likely 
 
3. What drug would you prefer to use if you had a headache in the next few 
days? Check ONE of the following options: 
 
      Drug N 
      Drug P 
      I would prefer the 2 agents equally 
      I would prefer neither agent 
 
4. The passages you just read mentioned a heartburn side effect and how often 
it might occur. From what you read, which explanation would YOU prefer to be 
given on its occurrence? Check ONE of the following options: 
 
 The first version (a focus on who WILL NOT get heartburn) 
 The second version (a focus on who WILL get heartburn)  
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 APPENDIX L 
INTERVIEW GUIDE FOR INTERVIEING RESPONDENTS 
 
Turn the record button on then please read participants ID code aloud 
first,    
 ID# ___________ Today Date….., 2007 
 
Mr/ Mrs/ Ms ________!  
 
Thanks for filling out the forms and sitting for this interview. All the 
information you provide should help us better understand how we might 
best discuss side effects of medicines with patients. If my questions or 
my pronunciation are not understandable, please stop me and ask me 
for clarification 
 
 
 What we will do now is this – I will go back to several of the choices you 
made in the survey you just completed. We are now interested in WHY you 
picked the selections you did. Again, there are no right or wrong answers; we 
are just interested in what may have gone through your mind as you chose. If 
you can give some detail on this, great. I might ask a few questions to follow-up. 
If you can’t really given any detail, then that is okay too. We will not press you 
for an answer. In other words, “I don’t know” or “I am not sure why I picked an 
answer” is fine as well.  
 Okay, any questions before we start? Again, this should take about ½ 
hour. 
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 Question 1: Study 1- Involving Form 6 and 7 
You have answered 3 questions (on scale of 1-100) twice with similar wording – 
once with no frequency (Form 6), and once with frequency (Form 7).  
 
*Exact question to ask subject would be one of these depend on their answers: 
 
1. I see that providing the percentages and frequencies of each 
side effect changed [increase or decrease] your answers.      
Showing them the Form 7 Q 5, 6, 7 ~ compare with Form 6 Q 1, 2, 3 
I see increase in likelihood of taking drug …. 
I see decrease in likelihood of taking drug …. 
Can you tell me why? I mean what made you change your answer? 
 
OR 
 
1. I see that providing the percentages and frequencies of each 
side effect did not change your answer  
Showing them the Form 7 Q 5, 6, 7 ~ compare with Form 6 Q 1, 2, 3 
I don’t see any increase or decrease in likelihood of taking these 
drugs,  
Can you tell me why?  
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 Question 2 and 3: Study 1, involving Forms 6, 7 
*This question will only be asked if their likelihood of one drug [which is on 
the scale of 1-100] is more than the other two (if there was no difference 
between their likelihood, no question will be asked) 
 
 
2. For the FIRST version [Form 6]: Why 
was your likelihood of taking drug __ 
more than drug __ and __? 
 
ª If their answers to the preference 
question (choosing a drug to take) were 
different, then will be asked why that 
was the case:   
I see your likelihood of taking drug __ is 
higher than__ and __.  
Why did you chose drug __ (or none) if 
YOU needed a painkiller? 
 
 
 
 
 
 
3. In the SECOND version [Form 7]: 
Why was your likelihood of taking 
drug __ more than drug __ and __? 
 
ª If their answers toward the preference 
question (choosing a drug to take) were 
different, then they will be asked why 
that was the case:  
I see your likelihood of taking drug __ is 
higher than__ and __. 
Why did you chose drug __ (or none) if 
YOU needed a painkiller. 
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 Question 4 and 5: Involving Form 6&7 (Q4&8) in Study 1 
 
Mr/Mrs. …. You had a mild/severe headache scenario. We just introduce 3 
drugs considering the effectiveness and side effects of them, now may I ask: 
 
4. Which aspect do you feel had more influence on your decision to choose 
drug __ the FIRST time (in Form 6, Q4)? 
 
 Effectiveness   Side effect information you received     
 
…..IF they choose “None”, ask what was the reason?  
 
 
5. Which aspect do you feel had more influence on your decision to choose 
drug __ the SECOND time (Form 7, Q8)?  
 
 Effectiveness   Side effects information you received     
  
     …..IF they choose “None”, ask what was the reason? 
 
Question 6 and 7 involving [Form 1] (does not apply to all) 
 
ª If they had any previous experience with side effects, answer this (question 8 
of Form 1) 
 
Interviewer Instructions  
- holding Form 1, show them to the respondent one at a time as reminder, 
and in the sequence to the questions below 
 
6. As you mentioned in Form 1 (Q8), you had experienced _________ . Did 
that fact affect your responses toward not taking any of the drug(s) with this / 
these side effects?  
 
 Yes      No 
 
(If answered yes please continue and ask next question)…  
 
7. If any medications – no matter how effective – had this side effect, would 
you still consider taking it? 
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 Study 1 
Comparing Question 9 of Form 8 and Question16 of Form 1 
 
   No preference 
 
 
If only the answers to the questions in these two forms differed, 
participants will be asked why? 
The exact possible question would be one of these: 
 
- I see in page 21 (Q9) you preferred the first version (a list of possible 
side effects with no frequency), then may I ask in question 16 (show 
them their answer) why you picked option 2 which means you liked list of 
side effects with the frequency of its occurrences? 
OR 
- I see in page 21 (Q9) you preferred the second version (a list of possible 
side effects with frequency), then may I ask in question 16 (show them 
their answer) why you picked option 1 which means you liked list of side 
effects with no frequency of its occurrences? 
OR 
I see in question 16 you picked no preference then in page 21(Q9) I 
asked you which version you preferred you chose version ___. Since 
both of these questions are quiet similar; May I ask what in this process 
made you realize that version___ is a better option to be presented with? 
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Study 2 (Form 9) 
 
Holding Form 9 and after showing it to the respondent as a reminder; ask these 
questions: 
 
 
 
 Note: those participants whom had a different likelihood of taking drug N and P 
only – answer next two questions. 
 
1) Why was your likelihood of taking drug ___more than drug ___? 
 
2) Which one did you think is more risky to take?  Drug N  Drug P 
 
At the end of interview: 
 
“Thank you so much for your participation.” 
 
